0001140361-26-011231 | 10-K | XBRL Viewer

Print Document

Business and Geographical Reporting Segments (Details) $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($) Segment	Dec. 31, 2024 USD ($)
Business and Geographical Reporting Segments [Abstract]
Number of operating segments (in Segment) \| Segment	2
Number of reportable segments not disclosed	true
International [Member]
Business and Geographical Reporting Segments [Abstract]
Long-lived assets \| $	$ 1.3	$ 1.3

Revision of Previously Issued Consolidated Financial Statements - Revision of Previously Issued Consolidated Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended					6 Months Ended		9 Months Ended	12 Months Ended
	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2025	Jun. 30, 2024	Sep. 30, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revision of Previously Issued Consolidated Financial Statements [Abstract]
Goodwill	$ 1,429	$ 1,429	$ 5,697	$ 5,697	$ 5,697	$ 1,429	$ 5,697	$ 5,697	$ 1,429	$ 1,429
Total assets	29,493	33,033	39,383	38,759	39,226	29,493	38,759	39,383	30,521	34,928
Accrued expenses and other current liabilities	5,948	7,240	7,643	5,776	5,445	5,948	5,776	7,643	6,155	7,364
Total current liabilities	12,551	13,600	13,165	11,301	11,764	12,551	11,301	13,165	26,741	13,396
Total liabilities	28,961	30,054	29,981	29,253	29,792	28,961	29,253	29,981	27,613	29,956
Accumulated deficit	(252,841)	(250,266)	(243,589)	(241,515)	(241,424)	(252,841)	(241,515)	(243,589)	(254,405)	(248,144)
Total stockholders’ equity	532	2,979	9,401	9,506	9,434	532	9,506	9,401	2,908	4,972	$ 12,688
Total liabilities and stockholders’ equity	29,493	33,033	39,383	38,759	39,226	29,493	38,759	39,383	30,521	34,928
General and administrative	2,997	2,263	3,621	2,202	2,708	5,260	4,910	8,531	10,184	10,896
Impairment of goodwill									0	4,268
Total operating expenses	6,616	5,482	6,891	5,455	6,083	12,098	11,538	18,429	22,581	28,477
Loss from operations	(2,310)	(1,705)	(1,605)	(478)	(2,887)	(4,015)	(3,365)	(4,970)	(4,700)	(9,255)
Net loss	$ (2,575)	$ (2,122)	$ (2,074)	$ (91)	$ (3,366)	$ (4,697)	$ (3,457)	$ (5,531)	$ (6,261)	$ (10,086)
Net loss per share of common stock, basic (in Dollars per share)	$ (0.62)	$ (0.51)	$ (0.51)	$ (0.03)	$ (0.1)	$ (1.13)	$ (0.99)	$ (1.5)	$ (1.35)	$ (2.65)
Net loss per share of common stock, diluted (in Dollars per share)	$ (0.62)	$ (0.51)	$ (0.51)	$ (0.03)	$ (0.1)	$ (1.13)	$ (0.99)	$ (1.5)	$ (1.35)	$ (2.65)
As Previously Reported [Member]
Revision of Previously Issued Consolidated Financial Statements [Abstract]
Goodwill	$ 2,658	$ 2,658	$ 6,519	$ 6,519	$ 6,519	$ 2,658	$ 6,519	$ 6,519		$ 2,658
Total assets	30,722	34,262	40,205	39,581	40,048	30,722	39,581	40,205		36,157
Accrued expenses and other current liabilities	7,401	8,779	8,524	6,608	6,269	7,401	6,608	8,524		8,593
Total current liabilities	14,004	15,139	14,046	12,133	12,588	14,004	12,133	14,046		14,625
Total liabilities	30,414	31,593	30,862	30,085	30,616	30,414	30,085	30,862		31,185
Accumulated deficit	(253,065)	(250,576)	(243,647)	(241,525)	(241,426)	(253,065)	(241,525)	(243,647)
Total stockholders’ equity	308	2,669	9,343	9,496	9,432	308	9,496	9,343
Total liabilities and stockholders’ equity	30,722	34,262	40,205	39,581	40,048	30,722	39,581	40,205		36,157
General and administrative	2,911	2,573	3,669	2,210	2,710	5,484	4,920	8,589		11,303
Impairment of goodwill										3,861
Total operating expenses	6,530	5,792	6,939	5,463	6,085	12,322	11,548	18,487
Loss from operations	(2,224)	(2,015)	(1,653)	(486)	(2,889)	(4,239)	(3,375)	(5,028)
Net loss	$ (2,489)	$ (2,432)	$ (2,122)	$ (99)	$ (3,368)	$ (4,921)	$ (3,467)	$ (5,589)
Net loss per share of common stock, basic (in Dollars per share)	$ (0.6)	$ (0.58)	$ (0.53)	$ (0.03)	$ (0.1)	$ (1.18)	$ (0.99)	$ (1.52)
Net loss per share of common stock, diluted (in Dollars per share)	$ (0.6)	$ (0.58)	$ (0.53)	$ (0.03)	$ (0.1)	$ (1.18)	$ (0.99)	$ (1.52)
Adjustment [Member]
Revision of Previously Issued Consolidated Financial Statements [Abstract]
Goodwill	$ (1,229)	$ (1,229)	$ (822)	$ (822)	$ (822)	$ (1,229)	$ (822)	$ (822)		(1,229)
Total assets	(1,229)	(1,229)	(822)	(822)	(822)	(1,229)	(822)	(822)		(1,229)
Accrued expenses and other current liabilities	(1,453)	(1,539)	(881)	(832)	(824)	(1,453)	(832)	(881)		(1,229)
Total current liabilities	(1,453)	(1,539)	(881)	(832)	(824)	(1,453)	(832)	(881)		(1,229)
Total liabilities	(1,453)	(1,539)	(881)	(832)	(824)	(1,453)	(832)	(881)		(1,229)
Accumulated deficit	224	310	58	10	2	224	10	58
Total stockholders’ equity	224	310	58	10	2	224	10	58
Total liabilities and stockholders’ equity	(1,229)	(1,229)	(822)	(822)	(822)	(1,229)	(822)	(822)		(1,229)
General and administrative	86	(310)	(48)	(8)	(2)	(224)	(10)	(58)		(407)
Impairment of goodwill										$ 407
Total operating expenses	86	(310)	(48)	(8)	(2)	(224)	(10)	(58)
Loss from operations	(86)	310	48	8	2	224	10	58
Net loss	$ (86)	$ 310	$ 48	$ 8	$ 2	$ 224	$ 10	$ 58
Net loss per share of common stock, basic (in Dollars per share)	$ (0.02)	$ 0.07	$ 0.02	$ 0	$ 0	$ 0.05	$ 0	$ 0.02
Net loss per share of common stock, diluted (in Dollars per share)	$ (0.02)	$ 0.07	$ 0.02	$ 0	$ 0	$ 0.05	$ 0	$ 0.02

Basis of Presentation and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2025

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation:

Principles of Consolidation

The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements include the accounts of the Company and Photomedex India Private Limited, its wholly-owned subsidiary in India. No operating activities have occurred within the Company’s subsidiary as of and during the years ended December 31, 2025 and 2024.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company’s significant estimates and judgments include revenue recognition with respect to deferred revenues and the contract term and valuation allowances of accounts receivable, inputs used when evaluating goodwill for impairment, inputs used in the valuation of contingent consideration, state sales and use tax accruals, the estimated useful lives of intangible assets, and the valuation allowance related to deferred tax assets. Actual results could differ from those estimates.

Concentrations of Credit Risk and Major Customers

The Company’s cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance coverage limit of $0.3 million per depositor, per FDIC-insured bank, per ownership category. Management has reviewed the financial statements of this institution and believes it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little credit risk to the Company.

Financial instruments that potentially subject the Company to concentrations of credit risk principally consist of cash equivalents and accounts receivable. The Company limits its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but it does not require collateral to secure amounts owed by its customers.

The Company had one customer, an international distributor, from which it primarily earns dermatology procedures equipment revenues, that accounted for 10% or more of the Company’s revenues for each of the years ended December 31, 2025 and 2024. Revenues from this customer were $3.4 million and $4.1 million, or 10.9% and 12.1%, of total net revenues during the years ended December 31, 2025 and 2024, respectively. There were no accounts receivable associated with this customer as of December 31, 2025 and 2024. Accounts receivable associated with two other customers as of December 31, 2025 and 2024, each of which accounted for 10% or more of the Company’s net accounts receivable, was $1.3 million and $2.2 million, or 31.1% and 42.2%, of net accounts receivable as of December 31, 2025 and 2024, respectively.

Cash and Cash Equivalents

The Company considers all highly-liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2025 and 2024, cash equivalents consisted of credit card transactions with settlement terms of less than five days.

Restricted Cash

As discussed more fully in Note 11, the Company was required to post an appellate bond for $1.3 million in the form of cash collateral with respect to a sales tax determination by the State of New York Tax Appeals Tribunal (“Tribunal”), which was recorded as restricted cash on the consolidated balance sheet as of December 31, 2024. During the year ended December 31, 2025, the state of New York executed on the appellate bond. There is no restricted cash as of December 31, 2025.

The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2025		2024

Cash and cash equivalents	$	7,912	$	7,261
Restricted cash		—		1,334
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	7,912	$	8,595

Accounts Receivable and Allowance for Credit Losses

Accounts receivable primarily relate to amounts due from customers, which are typically due within 30 to 90 days from invoice date. The Company provides credit to its customers in the normal course of business and maintains allowances for expected credit losses over the remaining contractual lives of its receivables, considering customer financial condition, historical loss experience with customers, current market economic conditions and forecasts of future economic conditions when appropriate. The Company does not require collateral or other security for accounts receivable. The Company also maintains allowances for estimated losses resulting from amounts deemed to be uncollectible from its customers. These allowances are for specific amounts on certain customer accounts based on facts and circumstances determined on a case-by-case basis. The Company writes off accounts receivable when they are considered uncollectible, and payments subsequently received on such receivables are credited to bad debt expense. The Company does not recognize interest accruing on accounts receivable past due.

The activity in the allowance for credit losses is summarized as follows (in thousands):

	December 31,
	2025			2024

Balance, beginning of year	$	433		$	222
Provision for expected losses		134			(179	)
Write-offs charged against the allowance		(16	)		141
Other adjustments		—			249
Balance, end of year	$	551		$	433

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined based on purchased cost for raw materials and all production cost related to the laser manufacturing process (labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods is classified as inventory. For the Company’s products, cost is determined on the first-in, first-out method. Work-in-process is immaterial, given the typically short manufacturing cycle and therefore, is disclosed in conjunction with raw materials.

The Company’s equipment for the treatment of skin disorders (e.g. the XTRAC) will either (i) be placed in a physician’s office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser for sale is accumulated in inventory, and the cost to build a laser for placement is accumulated in property and equipment.

Reserves for slow-moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trends.

Property and Equipment, net

Property and equipment are recorded at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Upon retirement or disposition, the applicable property and equipment amounts are deducted from the accounts and any gain or loss is recorded in the consolidated statements of operations. Depreciation and amortization are recognized using the straight-line method based on the estimated useful lives of the related assets. The Company uses an estimated useful life of three years for computers, hardware and software, five years for machinery and equipment, seven years for furniture and fixtures, and the lesser of the useful life or lease term for leasehold improvements.

Intangible Assets

Intangible assets consist of core technology, product technology, customer relationships, trademarks and distribution rights. Intangible assets are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from three to 12 years.

Goodwill

Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized, but is subject to an annual impairment test. The Company has two reporting units and goodwill is allocated to the reporting units (see Note 15).

The Company performs its goodwill impairment test on an annual basis in the fourth quarter of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded for the amount by which the carrying amount of the reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. In conjunction with the annual budgeting process during the fourth quarter of 2025, the Company reduced its overall project earnings, primarily as a result of tariffs and uncertainty caused by U.S. trade policies. Similarly, in conjunction with the annual budgeting process during the fourth quarter of 2024, the Company reduced its overall projected earnings. As a result, the Company bypassed the qualitative assessments of goodwill impairment and performed quantitative assessments by comparing the fair value of each reporting unit with its carrying amount. The Company recorded no impairment charge during the year ended December 31, 2025 and a $4.3 million impairment charge related to goodwill during the year ended December 31, 2024, which was the amount of the excess of the carrying value of the dermatology recurring procedures reporting unit over its fair value. The impairment charge for 2024 is included in impairment of goodwill within the consolidated statement of operations and was primarily driven by a decline in projected cash flows, including revenues and profitability. During 2025 and 2024, the fair values of the reporting units were determined using both a market and income approach, with the market approach given a 25% weighting and the income approach given a 75% weighting. Significant assumptions used in the income approach include growth and discount rates, profit margins and the Company’s weighted average cost of capital. Historical performance and management estimates of future performance were used to determine profit margins and growth rates.

Impairment of Long-Lived Assets and Intangibles

The Company reviews its long-lived assets and intangible assets subject to amortization for impairment whenever events or changes in circumstances indicate the carrying amount of an asset group may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset group to future net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group, less costs to sell. The Company did not record any charges related to asset impairment during the years ended December 31, 2025 and 2024.

Fair Value Measurements

The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires the use of observable inputs and minimizes the use of unobservable inputs. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

•

Level 1 – quoted market prices in active markets for identical assets or liabilities.

•

Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold.

The activity in the warranty accrual during the years ended December 31, 2025 and 2024 is summarized as follows (in thousands):

	December 31,
	2025			2024

Balance, beginning of year	$	315		$	303
Additions		100			156
Expirations and claims satisfied		(195	)		(144	)
Total		220			315
Less current portion within accrued expenses and other current liabilities		(157	)		(213	)
Balance within deferred revenues and other liabilities	$	63		$	102

Debt Issuance Costs

The Company capitalizes direct costs incurred to obtain debt financing and amortizes these costs to interest expense over the term of the debt using the effective interest method. These costs are recorded as a debt discount and are netted against the related debt on the Company’s consolidated balance sheets.

Contingent Consideration

In January 2022, the Company acquired certain assets related to the TheraClear devices from Theravant Corporation (“Theravant”). Theravant was eligible to receive future earnout payments upon the achievement of certain net revenue, gross profit and commercialization milestones (see Note 11). Due to uncertainties associated with the development of a new product line and the use of estimates and assumptions to determine the fair value of the contingent consideration, the amount ultimately paid in connection with the earnout may differ from the estimated fair value at the acquisition date. As the transaction was accounted for as an asset acquisition, a revaluation of the contingent consideration was only required if there was a significant change to the underlying valuation assumptions. The contingent consideration was adjusted upon resolution of the contingency and when the consideration was paid or became payable. Any difference between the cash payment and the amount accrued for contingent consideration resulted in an adjustment to the technology intangible asset. Contingent consideration expected to be paid within the next year is classified as current on the consolidated balance sheets.

During the year ended December 31, 2024, there were no significant changes to the Company’s projections of expected revenues and gross profits to be earned from TheraClear devices and, as such, the Company did not revalue the contingent consideration. During the year ended December 31, 2025, the Company was released from its outstanding obligations for contingent consideration and as a result the liability was derecognized (see Note 8).

Revenue Recognition

Revenues from the Company’s dermatology recurring procedures customers are earned by providing physicians with its laser products and charging the physicians a fee for a fixed number of treatment sessions or a fixed fee for a specified period of time not to exceed an agreed upon number of treatments; if that number is exceeded additional fees will have to be paid. The placement of the laser products at physician locations represents embedded leases which are accounted for as operating leases. For the lasers placed-in service under these arrangements, the terms of the domestic arrangements are generally 36 months with automatic one-year renewals and include a termination clause that can be effected at any time by either party with 30 to 60 days’ notice. Amounts paid are generally non-refundable. Sales of access codes for a fixed number of treatment sessions are considered variable treatment code payments and are recognized as revenue ratably over a 30 or 60 day period. Sales of access codes for a specified period of time are recognized as revenue on a straight-line basis as the lasers are being used over the term specified in the agreement. Variable treatment code payments that will be paid only if the customer exceeds the agreed upon number of treatments are recognized only when such treatments are being exceeded and used. Internationally, the Company generally sells access codes for a fixed amount on a monthly basis to its distributors and the terms are generally 48 months, with termination in the event of the customers’ failure to remit payments timely, and include a potential buy-out at the end of the term of the contract. Currently, this is the only foreign recurring revenue. Prepaid amounts recorded in deferred revenue and customer deposits recorded in accounts payable are recognized as revenue over the lease term in the patterns described above. Pricing is fixed with the customer. With respect to lease and non-lease components, the Company adopted the practical expedient to account for the arrangement as a single lease component.

Revenues from the Company’s dermatology procedures equipment are recognized when control of the promised goods or services is transferred to its customers or distributors, in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. Accordingly, the Company determines revenue recognition through the following steps:

•

identification of the contract, or contracts, with a customer;

•

identification of the performance obligations in the contract;

•

determination of the transaction price;

•

allocation of the transaction price to the performance obligations in the contract; and

•

recognition of revenue when, or as, performance obligations are satisfied.

Accounting for the Company’s contracts involves the use of significant judgments and estimates including determining the separate performance obligations, allocating the transaction price to the different performance obligations and determining the method to measure the entity’s performance toward satisfaction of performance obligations that most faithfully depicts when control is transferred to the customer. The Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of the standalone selling price for each distinct good or service in the contract. The Company maximizes the use of observable inputs by beginning with average historical contractual selling prices and adjusting as necessary and on a consistent and rational basis for other inputs such as pricing trends, customer types, volumes and changing cost and margins.

Revenues from dermatology procedures equipment are recognized when control of the promised products is transferred to either the Company’s distributors or end-user customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products (the transaction price). Control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment and legal title must have passed to the customer. The Company ships most of its products FOB shipping point, and as such, the Company primarily transfers control and records revenue upon shipment. From time to time the Company will grant certain customers, for example governmental customers, FOB destination terms, and the transfer of control for revenue recognition occurs upon receipt. The Company has elected to recognize the cost of freight and shipping activities as fulfillment costs. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenues.

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2025		2024

Dermatology recurring procedures	$	21,478	$	21,171
Dermatology procedures equipment		9,218		12,391
Total net revenues	$	30,696	$	33,562

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international dermatology recurring procedures, the Company’s only long-term arrangements, as of December 31, 2025 (in thousands):

Years ending December 31:
2026	$	1,983
2027		1,798
2028		1,236
2029		266
	$	5,283

Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year, which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include the potential obligation to perform under extended warranties and service contracts but exclude any dermatology procedures equipment accounted for as leases. As of December 31, 2025 and 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was $0.3 million and $0.5 million, respectively, and the Company expects to recognize $0.2 million and $0.2 million, respectively, of the remaining performance obligations within one year and the remainder over one to three years. Contract assets primarily relate to the Company’s rights to consideration for work completed in relation to its services performed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. Currently, the Company does not have any contract assets which have not transferred to a receivable.

Contract liabilities primarily relate to extended warranties and service contracts where the Company has received payments but has not yet satisfied the related performance obligations. The allocations of the transaction price are based on the price of standalone warranty contracts sold in the ordinary course of business. The advance consideration received from customers for the warranty services is a contract liability that is recognized ratably over the warranty period. As of both December 31, 2025 and 2024, the $0.2 million of short-term contract liabilities is presented as deferred revenues and the $0.1 million and $0.3 million of long-term contract liabilities, respectively, is presented within deferred revenues and other liabilities on the consolidated balance sheets. For the years ended December 31, 2025 and 2024, the Company recognized $0.2 million and $0.3 million, respectively, as revenue from amounts classified as contract liabilities (i.e. deferred revenues) as of December 31, 2024 and 2023.

With respect to contract acquisition costs, the Company applies the practical expedient and expenses these costs immediately.

Engineering and Product Development

Engineering and product development costs associated with research, new product development and product redesign are expensed as incurred.

Advertising Costs

Advertising costs are expensed as incurred and included in selling and marketing expenses within the Company’s consolidated statements of operations. The Company recognized advertising costs of $0.8 million and $1.0 million during the years ended December 31, 2025 and 2024, respectively.

Stock-Based Compensation

The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the requisite service period of the awards.

Estimating the fair value of share-based awards requires the input of subjective assumptions, including the expected term of the options and stock price volatility. The Company accounts for forfeitures of stock option awards as they occur. The estimated fair value of restricted stock awards is equal to the Company’s common stock price at the grant date. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of stock-option awards represent management’s estimate and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities, as well as on net operating loss carryforwards, and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is not more likely than not that all or some portion of the deferred tax asset will be realized.

The Company recognizes the tax effects of uncertain tax positions only if the position is “more-likely-than-not” to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the “more-likely-than-not” threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded. The Company has no uncertain tax positions as of December 31, 2025. The Company includes interest and penalties related to income tax obligations within income tax expense. The Company’s tax years are still under open status from 2022 to present.

Employee Retention Credit

The Employee Retention Credit (“ERC”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) is a refundable tax credit which encouraged businesses to keep employees on the payroll during the COVID-19 pandemic. Eligible employers could qualify for up to $7.0 thousand of credit for each employee based on qualified wages paid after December 31, 2020 and before January 1, 2022. Qualified wages are any wages paid to an employee (for employers that averaged fewer than 100 full-time employees in 2019) or the wages paid to an employee for the time that the employee is providing and not providing services (for employers that averaged more than 500 full-time employees in 2019) due to an economic hardship, specifically, either (1) a full or partial suspension of operations by order of a governmental authority due to COVID-19, or (2) a significant decline in gross receipts. The Company recognized $0.9 million of ERC upon receipt as other income in the consolidated statement of operations for the year ended December 31, 2024. There was no such activity for the year ended December 31, 2025.

Net Loss Per Share

Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities such as unvested restricted stock awards, stock options and warrants for common stock which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same as for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2025		2024

Stock options		725,726		521,726
Common stock warrants		80,000		80,000
Restricted stock units		2,265		2,265
		807,991		603,991

Accounting Pronouncements Recently Adopted

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in this ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted the guidance in ASU 2023-09 for the year ended December 31, 2025, and it is being applied prospectively to its consolidated financial statement disclosures.

Recent Accounting Pronouncements Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as subsequently amended by ASU 2025-01 to clarify the effective date, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements and footnote disclosures.

In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which simplifies the estimation of credit losses on current accounts receivable and contract assets by allowing the election of a practical expedient to assume that the current conditions as of the consolidated balance sheet date will remain unchanged for the remaining life of the asset when developing a reasonable and supportable forecast as part of estimating expected credit losses on these assets. The guidance in this ASU is effective for fiscal years beginning after December 15, 2025 and for interim periods within those fiscal years. Early adoption is permitted. If adopted in an interim period, entities are required to apply the new guidance as of the beginning of the annual reporting period that includes such interim period. The Company does not expect this ASU to have a material impact on its consolidated financial statements.

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270), which clarifies the guidance in Topic 270 to improve the consistency of interim financing reporting. The ASU provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The guidance in this ASU is effective for interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements.

Organization and Nature of Business	12 Months Ended
Organization and Nature of Business	Dec. 31, 2025
Organization and Nature of Business [Abstract]
Organization and Nature of Business	1. Organization and Nature of Business Background STRATA Skin Sciences, Inc. (the “Company”) is a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. In January 2022, the Company acquired the TheraClear® Acne Therapy System to broaden its opportunities with expansion potential in the acne care market. The Company markets the device under the brand name TheraClear® X. The Company’s shares of common stock were delisted from The Nasdaq Capital Market at the opening of business on February 19, 2026 and are now quoted over the counter (“OTC”). See Note 16 for additional information. Impact of Tariffs In 2025, the U.S. introduced trade policy actions that have increased import tariffs across a wide range of countries at various rates, with certain exemptions. To the extent that trade tariffs and other restrictions imposed by the U.S. or other countries increase the price of, or limit the amount of, the Company’s products or components or materials used in its products imported into the U.S., or create adverse tax consequences, the revenues, costs, or gross profit of the Company’s products and services, primarily in the Dermatology Procedures Equipment segment, may be adversely affected and the demand from its customers may be diminished. Uncertainty surrounding international trade policy and regulations as well as disputes and protectionist measures could also have an adverse effect on consumer confidence and spending and may impact the Company’s results of operations. Impact of Middle East Conflict In early 2026, geopolitical tensions in the Middle East escalated significantly, including military conflict involving the U.S., Israel and Iran. While the situation remains fluid and continues to evolve, these developments have contributed to increased regional instability, including disruptions to airspace and heightened volatility in global energy markets. Although the Company has not experienced a material impact on its operations as of the date of issuance of these consolidated financial statements, continued or expanded conflict in the region could adversely affect global economic conditions, supply chains, transportation logistics, and customer demand, which in turn could impact the Company’s business and results of operations. Liquidity and Going Concern The Company has historically experienced recurring losses and has been dependent on raising capital from the sale of securities in order to continue to operate. In October 2021, the Company entered into an equity distribution agreement with an investment bank under which, as of December 31, 2025, the Company could sell up to an additional $5.1 million of its common stock in registered “at-the-market” offerings, subject to certain limitations. As of the date that the consolidated financial statements were issued, the Company may not sell any of its shares of common stock under the equity distribution agreement because it deregistered the unsold shares following the delisting of its common stock. Management has evaluated the Company’s ability to meet its financial obligations as they become due within the next 12 months following the issuance of these consolidated financial statements. The delisting of the Company’s shares constitutes an event of default under the Senior Term Facility (see Note 10), which has continued through the date of issuance of these consolidated financial statements. The lender reserves any and all rights and remedies available to it under the Senior Term Facility, including, without limitation, its right to choose to accelerate the debt and seek immediate repayment in full. As a result, all of the Company’s long-term debt has been classified as current in the consolidated balance sheet, resulting in negative working capital. This, combined with its history of operating losses, raises substantial doubt about the Company’s ability to continue as a going concern for the next 12 months from the date that the consolidated financial statements were issued. Specifically, the Company’s ability to meet its obligations and continue operations is dependent upon regaining compliance with its debt covenants, modifying its existing debt facility, or successfully securing additional sources of liquidity and financing, as well as addressing other challenges, including market conditions that may negatively impact its ability to access capital. These conditions include, but are not limited to, potential future pandemics, changes in U.S. trade policies, supply chain disruptions, customer behavior, and rising interest rates, and could interfere with the Company’s ability to access financing and on favorable terms. Management is actively evaluating various strategies to address the Company’s liquidity concerns, including exploring financing alternatives and pursuing other strategic initiatives. However, there can be no assurance that these efforts will be successful or sufficient to mitigate the substantial doubt regarding the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared under the assumption that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. These financial statements do not include any adjustments that might result from the Company’s inability to continue as a going concern.

Stock-Based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Stock-Based Compensation [Abstract]
Stock-based compensation expense	$ 643	$ 427
Selling and Marketing [Member]
Stock-Based Compensation [Abstract]
Stock-based compensation expense	100	7
General and Administrative [Member]
Stock-Based Compensation [Abstract]
Stock-based compensation expense	$ 543	$ 420

Income Taxes - Components of Deferred Tax Liability for Federal Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Deferred tax assets:
Net operating loss carryforwards	$ 49,215	$ 46,295
Intangible assets	2,114	2,308
Inventories	73	57
Reserves and accrued expenses	1,539	2,068
Stock-based compensation	220	162
Operating lease liabilities	242	305
Interest expense limitation carryover	1,270	1,024
Goodwill	318	239
Property and equipment	264	0
Gross deferred tax assets	55,255	52,458
Less: valuation allowance	(55,013)	(51,671)
Net deferred tax assets	242	787
Property and equipment	0	(478)
Operating lease right-of-use assets	(242)	(309)
Gross deferred tax liabilities	(242)	(787)
Net deferred tax liability	$ 0	$ 0

Business and Geographical Reporting Segments - Disaggregation of Revenue by Geographical Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Business and Geographical Reporting Segments [Abstract]
Revenues	$ 30,696	$ 33,562
Dermatology Recurring Procedures [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	21,478	21,171
Dermatology Procedures Equipment [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	9,218	12,391
Domestic [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	20,584	20,888
China [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	3,355	4,069
Middle East [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	1,896	2,766
Other Foreign [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	4,861	5,839
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	21,478	21,171
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	9,218	12,391
Operating Segments [Member] \| Domestic [Member] \| Dermatology Recurring Procedures [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	19,572	19,531
Operating Segments [Member] \| Domestic [Member] \| Dermatology Procedures Equipment [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	1,012	1,357
Operating Segments [Member] \| China [Member] \| Dermatology Recurring Procedures [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	0	0
Operating Segments [Member] \| China [Member] \| Dermatology Procedures Equipment [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	3,355	4,069
Operating Segments [Member] \| Middle East [Member] \| Dermatology Recurring Procedures [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	0	0
Operating Segments [Member] \| Middle East [Member] \| Dermatology Procedures Equipment [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	1,896	2,766
Operating Segments [Member] \| Other Foreign [Member] \| Dermatology Recurring Procedures [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	1,906	1,640
Operating Segments [Member] \| Other Foreign [Member] \| Dermatology Procedures Equipment [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues	$ 2,955	$ 4,199

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Inventories (Details) - USD ($) $ in Thousands	12 Months Ended
Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Inventories [Abstract]
Inventories wrote off	$ 0	$ 162

Leases

12 Months Ended

Dec. 31, 2025

Leases [Abstract]

Leases

7. Leases

The Company recognizes right-of-use assets (“ROU assets”) and operating lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than 12 months. The Company adopted the short-term accounting election for leases with a duration of less than one year. The Company leases its facilities and certain IT and office equipment under non-cancellable operating leases. All of the Company’s leasing arrangements are classified as operating leases with remaining lease terms ranging from one to four years. In March 2024, the Company terminated the existing lease for its California facility and concurrently executed a new lease that effectively extended the term of the lease for five years, which has been accounted for as a lease modification. The ROU asset and operating lease liability were remeasured at the modification date, resulting in an increase to both balances of $1.0 million during the year ended December 31, 2024. There were no lease modifications during the year ended December 31, 2025.

Operating lease costs were $0.5 million for each of the years ended December 31, 2025 and 2024. Cash paid for amounts included in the measurement of operating lease liabilities was $0.5 million for each of the years ended December 31, 2025 and 2024. As of December 31, 2025 and 2024, the weighted average incremental borrowing rate was 12.70% and 12.18%, respectively, and the weighted average remaining lease term was 3.6 years and 4.1 years, respectively.

The following table summarizes the Company’s operating lease maturities as of December 31, 2025 (in thousands):

Years ending December 31:
2026	$	334
2027		290
2028		301
2029		232
Total remaining lease payments		1,157
Less: imputed interest		(238	)
Total lease liabilities	$	919

With respect to lease and non-lease components, the Company adopted the practical expedient to account for the lessee arrangement as a single lease component.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Inventories (Tables)

12 Months Ended

Dec. 31, 2025

Inventories [Abstract]

Inventories

Inventories consist of the following (in thousands):

	December 31,
	2025		2024

Raw materials and work-in-process	$	2,601	$	2,041
Finished goods		213		205
	$	2,814	$	2,246

Basis of Presentation and Summary of Significant Accounting Policies - Accrued Warranty Costs Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Balance, beginning of year	$ 315	$ 303
Additions	100	156
Expirations and claims satisfied	(195)	(144)
Total	220	315
Less current portion within accrued expenses and other current liabilities	(157)	(213)
Balance within deferred revenues and other liabilities	$ 63	$ 102

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2025

Long-Term Debt [Abstract]

Future Payments for Long-term Debt

Future minimum principal payments at December 31, 2025 are as follows (in thousands):

Years ending December 31:
2026	$	15,000
		15,000
Exit fee		600
		15,600
Less: unamortized debt discount		(251	)
		15,349
Less: current portion of long-term debt		(15,349	)
Long-term debt, net	$	—

Basis of Presentation and Summary of Significant Accounting Policies (Details) $ in Thousands		12 Months Ended
	Oct. 22, 2024 USD ($)	Dec. 31, 2025 USD ($) Customer Unit	Dec. 31, 2024 USD ($) Customer
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Revenues		$ 30,696	$ 33,562
Accounts receivable		$ 4,121	$ 5,253
Credit card transaction settlement term		5 days	5 days
Appellate bond of company	$ 1,300
Restricted cash		$ 0	$ 1,334
Number of reporting units (in Unit) \| Unit		2
Goodwill impairment		$ 0	4,268
Asset impairment charges		0	0
Future undiscounted fixed payments from international recurring revenue customers		300	500
Short-term contract liabilities		200	200
Long-term contract liabilities		100	300
Contract liabilities recognized as revenue		200	300
Advertising expense		800	1,000
Other income		0	864
Employee Retention Credit [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Other income		$ 0	$ 900
Minimum [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Estimated useful life		3 years
Standard warranty period		1 year
Offered warranty period		3 years
Maximum [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Estimated useful life		12 years
Standard warranty period		2 years
Offered warranty period		4 years
Computers, Hardware and Software [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Property and equipment, net, useful life		3 years
Machinery and Equipment [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Property and equipment, net, useful life		5 years
Furniture and Fixtures [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Property and equipment, net, useful life		7 years
Lasers Placed-in Service [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Lease term		36 months
Renewal term		1 year
Lasers Placed-in Service [Member] \| Minimum [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Notice period to cancel contract agreement		30 days
Lasers Placed-in Service [Member] \| Maximum [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Notice period to cancel contract agreement		60 days
South Korea [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Lease term		48 months
Two Other Customers [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Number of major customers (in Customer) \| Customer		2	2
Customer Concentration Risk [Member] \| Revenue [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Number of major customers (in Customer) \| Customer		1	1
Customer Concentration Risk [Member] \| Revenue [Member] \| One Customer [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Revenues		$ 3,400	$ 4,100
Concentration risk percentage		10.90%	12.10%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| One Customer [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Accounts receivable		$ 0	$ 0
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Two Other Customers [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Concentration risk percentage		31.10%	42.20%
Accounts receivable		$ 1,300	$ 2,200
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Future undiscounted fixed payments from international recurring revenue customers			$ 200
Expected timing of satisfaction period			1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| Minimum [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Expected timing of satisfaction period			1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| Maximum [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Expected timing of satisfaction period			3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Future undiscounted fixed payments from international recurring revenue customers		$ 200
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 \| Minimum [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 \| Maximum [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Expected timing of satisfaction period		3 years
Market Approach [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Percentage of fair value weighting market approach given		25.00%
Income Approach [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Percentage of fair value weighting market approach given		75.00%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Income Taxes [Abstract]

Components of Income Tax Expense

Income tax expense consists of the following (in thousands):

	Year Ended December 31,
	2025		2024

Current:
Federal	$	—	$	—
State		12		16
		12		16
Deferred:
Federal		—		(107	)
State		—		(79	)
		—		(186	)
Provision for (benefit from) income taxes	$	12	$	(170	)

Cash Paid for Income Taxes, Net of Refunds Received

Cash paid for income taxes, net of refunds received, by jurisdiction pursuant to the disclosure requirements of ASU 2023-09 is as follows (in thousands):

	Year Ended December 31,
	2025		2024
Federal	$	—	$	—
State
Texas		9		10
Cash paid for income taxes, net of refunds received	$	9	$	10

Components of Deferred Tax Liability for Federal Income Taxes

Significant components of the Company’s deferred tax liability for federal income taxes consist of the following (in thousands):

	December 31,
	2025			2024
Deferred tax assets:
Net operating loss carryforwards	$	49,215		$	46,295
Intangible assets		2,114			2,308
Inventories		73			57
Reserves and accrued expenses		1,539			2,068
Stock-based compensation		220			162
Operating lease liabilities		242			305
Interest expense limitation carryover		1,270			1,024
Goodwill		318			239
Property and equipment		264			—
Gross deferred tax assets		55,255			52,458
Less: valuation allowance		(55,013	)		(51,671	)
		242			787
Deferred tax liabilities:
Property and equipment		—			(478	)
Operating lease right-of-use assets		(242	)		(309	)
Gross deferred tax liabilities		(242	)		(787	)
Net deferred tax liability	$	—		$	—

Net Operating Loss Carryforwards

The Company had net operating loss (“NOL”) carryforwards for federal and state income tax purposes as follows (in thousands):

	December 31,
	2025		2024

Federal	$	206,801	$	203,490
State	$	68,999	$	62,819

Reconciliation of Income Tax Expense

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows in accordance with the adoption of ASU 2023-09, which became effective in the year ended December 31, 2025 (numbers in thousands):

	Year Ended December 31, 2025

Federal tax expense at statutory rate	$	(1,312	)	21.00	%
State and local tax, net of federal benefit
California		—		—	%
New York State		—		—	%
New Jersey		—		—	%
Florida		—		—	%
Other		9		(0.15	)%
Change in valuation allowance		738		(11.81	)%
Nontaxable or nondeductible items
Nondeductible meal and entertainment expenses		97		(1.55	)%
Nondeductible incentive stock option compensation		83		(1.33	)%
Other		—		—	%
Other adjustments
NOL expiration		476		(7.62	)%
Other		(79	)	1.27	%
Effective income tax rate	$	12		(0.19	)%

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:

	Year Ended December 31, 2024

Federal tax expense at statutory rate	21.00	%
State tax, net of federal benefit	(0.12)	%
Permanent differences	(1.15)	%
Other difference and true ups	(3.13)	%
Change in valuation allowance	(14.94)	%
Effective income tax rate	1.66	%

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2025

Stock-Based Compensation [Abstract]

Share-based Compensation Expense

The Company measures share‑based awards at their grant‑date fair value and records compensation expense on a straight‑line basis over the requisite service period of the awards. The Company recorded share‑based compensation expense (for all awards and modifications, if any) in the accompanying consolidated statements of operations as follows (in thousands):

	Year Ended December 31,
	2025		2024

Selling and marketing	$	100	$	7
General and administrative		543		420
	$	643	$	427

Stock Option Activity

The following table summarizes stock option activity for the years ended December 31, 2025 and 2024:

	Number of Shares Under Option Plan			Weighted-Average Exercise Price per Option		Weighted-Average Remaining Contractual Term (in years)

Outstanding at January 1, 2024		772,864		$	11.07
Granted		70,000		$	3.22
Forfeited and expired		(321,138	)	$	14.07
Outstanding at December 31, 2024		521,726		$	8.16		7.88
Granted		238,000		$	2.55
Forfeited and expired		(34,000	)	$	12.30
Outstanding at December 31, 2025		725,726		$	6.13		7.89
Exercisable at December 31, 2025		317,251		$	9.15		6.79
Vested and expected to vest at December 31, 2025		725,726		$	6.13		7.89

Weighted Average Assumption Used for Grant Date Fair Value of Option Grants

For the years ended December 31, 2025 and 2024, the grant date fair value of all option grants was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions:

	Year Ended December 31,
	2025			2024

Expected term (in years)		6.5			6.46
Expected volatility		77.58	%		77.93	%
Risk-free rate		4.26	%		3.91	%
Dividend yield		0.00	%		0.00	%

Restricted Stock Units

Restricted stock units have historically been issued to certain board members. Activity in restricted stock units is summarized in the following table:

	Number of Units			Weighted-Average Grant Date Fair Value

Unvested at January 1, 2024		2,265		$	10.30
Vested		(2,265	)	$	10.30
Unvested at December 31, 2024		—		$	—

Revision of Previously Issued Consolidated Financial Statements

12 Months Ended

Dec. 31, 2025

Revision of Previously Issued Consolidated Financial Statements [Abstract]

Revision of Previously Issued Consolidated Financial Statements

3. Revision of Previously Issued Consolidated Financial Statements

Revisions

During the third quarter of 2025, the Company identified an error in its methodology for accruing sales tax liabilities that had resulted in a cumulative overstatement of accrued expenses and sales tax expense. The overstatement of accrued expenses resulted in an understatement of the carrying value of the dermatology recurring procedures reporting unit. During the years ended December 31, 2023 and 2024, the Company recorded impairment charges for the excess of the carrying value of the dermatology recurring procedures reporting unit over its fair value. The understatement of the carrying value for this reporting unit, as a result of the overstatement of accrued expenses and sales tax expense, resulted in an additional goodwill impairment charge for the years ended December 31, 2023 and 2024. The error had no net impact on accumulated deficit as of January 1, 2024, but impacted subsequent quarterly and annual reporting periods through June 30, 2025. The Company assessed the materiality of the error on prior period consolidated financial statements in accordance with Securities and Exchange Commission (“SEC”) Staff Accounting Bulletins No. 99 and No. 108, as codified in ASC 250, Accounting Changes and Error Corrections. Based on this assessment, in consideration of both quantitative and qualitative factors, the Company concluded that the error is not material to any previously presented interim or annual financial statements. The Company revised its financial statements for the periods impacted.

The following tables set forth the effects of the adjustment on affected items within the Company’s previously reported consolidated balance sheets for all impacted periods (in thousands):

	March 31, 2024
	As Previously Reported			Adjustment			As Revised

Goodwill	$	6,519		$	(822	)	$	5,697
Total assets	$	40,048		$	(822	)	$	39,226
Accrued expenses and other current liabilities	$	6,269		$	(824	)	$	5,445
Total current liabilities	$	12,588		$	(824	)	$	11,764
Total liabilities	$	30,616		$	(824	)	$	29,792
Accumulated deficit	$	(241,426	)	$	2		$	(241,424	)
Total stockholders’ equity	$	9,432		$	2		$	9,434
Total liabilities and stockholders’ equity	$	40,048		$	(822	)	$	39,226

	June 30, 2024
	As Previously Reported			Adjustment			As Revised

Goodwill	$	6,519		$	(822	)	$	5,697
Total assets	$	39,581		$	(822	)	$	38,759
Accrued expenses and other current liabilities	$	6,608		$	(832	)	$	5,776
Total current liabilities	$	12,133		$	(832	)	$	11,301
Total liabilities	$	30,085		$	(832	)	$	29,253
Accumulated deficit	$	(241,525	)	$	10		$	(241,515	)
Total stockholders’ equity	$	9,496		$	10		$	9,506
Total liabilities and stockholders’ equity	$	39,581		$	(822	)	$	38,759

	September 30, 2024
	As Previously Reported			Adjustment			As Revised

Goodwill	$	6,519		$	(822	)	$	5,697
Total assets	$	40,205		$	(822	)	$	39,383
Accrued expenses and other current liabilities	$	8,524		$	(881	)	$	7,643
Total current liabilities	$	14,046		$	(881	)	$	13,165
Total liabilities	$	30,862		$	(881	)	$	29,981
Accumulated deficit	$	(243,647	)	$	58		$	(243,589	)
Total stockholders’ equity	$	9,343		$	58		$	9,401
Total liabilities and stockholders’ equity	$	40,205		$	(822	)	$	39,383

	December 31, 2024
	As Previously Reported		Adjustment			As Revised

Goodwill	$	2,658	$	(1,229	)	$	1,429
Total assets	$	36,157	$	(1,229	)	$	34,928
Accrued expenses and other current liabilities	$	8,593	$	(1,229	)	$	7,364
Total current liabilities	$	14,625	$	(1,229	)	$	13,396
Total liabilities	$	31,185	$	(1,229	)	$	29,956
Total liabilities and stockholders’ equity	$	36,157	$	(1,229	)	$	34,928

	March 31, 2025
	As Previously Reported			Adjustment			As Revised

Goodwill	$	2,658		$	(1,229	)	$	1,429
Total assets	$	34,262		$	(1,229	)	$	33,033
Accrued expenses and other current liabilities	$	8,779		$	(1,539	)	$	7,240
Total current liabilities	$	15,139		$	(1,539	)	$	13,600
Total liabilities	$	31,593		$	(1,539	)	$	30,054
Accumulated deficit	$	(250,576	)	$	310		$	(250,266	)
Total stockholders’ equity	$	2,669		$	310		$	2,979
Total liabilities and stockholders’ equity	$	34,262		$	(1,229	)	$	33,033

	June 30, 2025
	As Previously Reported			Adjustment			As Revised

Goodwill	$	2,658		$	(1,229	)	$	1,429
Total assets	$	30,722		$	(1,229	)	$	29,493
Accrued expenses and other current liabilities	$	7,401		$	(1,453	)	$	5,948
Total current liabilities	$	14,004		$	(1,453	)	$	12,551
Total liabilities	$	30,414		$	(1,453	)	$	28,961
Accumulated deficit	$	(253,065	)	$	224		$	(252,841	)
Total stockholders’ equity	$	308		$	224		$	532
Total liabilities and stockholders’ equity	$	30,722		$	(1,229	)	$	29,493

The following tables set forth the effects of the adjustment on affected items within the Company’s previously reported consolidated statements of operations for all impacted periods (in thousands, except per share data):

	Three Months Ended March 31, 2024
	As Previously Reported			Adjustment			As Revised

General and administrative	$	2,710		$	(2	)	$	2,708
Total operating expenses	$	6,085		$	(2	)	$	6,083
Loss from operations	$	(2,889	)	$	2		$	(2,887	)
Net loss	$	(3,368	)	$	2		$	(3,366	)
Net loss per share of common stock, basic and diluted	$	(0.10	)	$	—		$	(0.10	)

	Three Months Ended June 30, 2024
	As Previously Reported			Adjustment			As Revised

General and administrative	$	2,210		$	(8	)	$	2,202
Total operating expenses	$	5,463		$	(8	)	$	5,455
Loss from operations	$	(486	)	$	8		$	(478	)
Net loss	$	(99	)	$	8		$	(91	)
Net loss per share of common stock, basic and diluted	$	(0.03	)	$	—		$	(0.03	)

	Six Months Ended June 30, 2024
	As Previously Reported			Adjustment			As Revised

General and administrative	$	4,920		$	(10	)	$	4,910
Total operating expenses	$	11,548		$	(10	)	$	11,538
Loss from operations	$	(3,375	)	$	10		$	(3,365	)
Net loss	$	(3,467	)	$	10		$	(3,457	)
Net loss per share of common stock, basic and diluted	$	(0.99	)	$	—		$	(0.99	)

	Three Months Ended September 30, 2024
	As Previously Reported			Adjustment			As Revised

General and administrative	$	3,669		$	(48	)	$	3,621
Total operating expenses	$	6,939		$	(48	)	$	6,891
Loss from operations	$	(1,653	)	$	48		$	(1,605	)
Net loss	$	(2,122	)	$	48		$	(2,074	)
Net loss per share of common stock, basic and diluted	$	(0.53	)	$	0.02		$	(0.51	)

	Nine Months Ended September 30, 2024
	As Previously Reported			Adjustment			As Revised

General and administrative	$	8,589		$	(58	)	$	8,531
Total operating expenses	$	18,487		$	(58	)	$	18,429
Loss from operations	$	(5,028	)	$	58		$	(4,970	)
Net loss	$	(5,589	)	$	58		$	(5,531	)
Net loss per share of common stock, basic and diluted	$	(1.52	)	$	0.02		$	(1.50	)

	Year Ended December 31, 2024
	As Previously Reported		Adjustment			As Revised

General and administrative	$	11,303	$	(407	)	$	10,896
Impairment of goodwill	$	3,861	$	407		$	4,268

	Three Months Ended March 31, 2025
	As Previously Reported			Adjustment			As Revised

General and administrative	$	2,573		$	(310	)	$	2,263
Total operating expenses	$	5,792		$	(310	)	$	5,482
Loss from operations	$	(2,015	)	$	310		$	(1,705	)
Net loss	$	(2,432	)	$	310		$	(2,122	)
Net loss per share of common stock, basic and diluted	$	(0.58	)	$	0.07		$	(0.51	)

	Three Months Ended June 30, 2025
	As Previously Reported			Adjustment			As Revised

General and administrative	$	2,911		$	86		$	2,997
Total operating expenses	$	6,530		$	86		$	6,616
Loss from operations	$	(2,224	)	$	(86	)	$	(2,310	)
Net loss	$	(2,489	)	$	(86	)	$	(2,575	)
Net loss per share of common stock, basic and diluted	$	(0.60	)	$	(0.02	)	$	(0.62	)

	Six Months Ended June 30, 2025
	As Previously Reported			Adjustment			As Revised

General and administrative	$	5,484		$	(224	)	$	5,260
Total operating expenses	$	12,322		$	(224	)	$	12,098
Loss from operations	$	(4,239	)	$	224		$	(4,015	)
Net loss	$	(4,921	)	$	224		$	(4,697	)
Net loss per share of common stock, basic and diluted	$	(1.18	)	$	0.05		$	(1.13	)

The adjustment had no net effect on the Company’s previously reported cash flows from operating activities, and it had no effect on the previously reported cash flows from investing and financing activities.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation, including the presentation of foreign revenues within the Company’s business and geographical reporting segment disclosures and the classification of certain international service fees between cost of revenues and selling and marketing expenses. These reclassifications had no impact on the previously reported total foreign revenues or loss from operations by reporting segment in the consolidated financial statements. The amounts for total operating expenses “As Previously Reported” above include the impact of the international service fees reclassification.

Leases (Tables)

12 Months Ended

Dec. 31, 2025

Leases [Abstract]

Operating Lease Maturities

The following table summarizes the Company’s operating lease maturities as of December 31, 2025 (in thousands):

Years ending December 31:
2026	$	334
2027		290
2028		301
2029		232
Total remaining lease payments		1,157
Less: imputed interest		(238	)
Total lease liabilities	$	919

Basis of Presentation and Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Cash and cash equivalents	$ 7,912	$ 7,261
Restricted cash	0	1,334
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$ 7,912	$ 8,595	$ 8,118

Basis of Presentation and Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Potential common stock equivalents (in Shares)	807,991	603,991
Stock Options [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Potential common stock equivalents (in Shares)	725,726	521,726
Common Stock Warrants [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Potential common stock equivalents (in Shares)	80,000	80,000
Restricted Stock Units [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Potential common stock equivalents (in Shares)	2,265	2,265

Revision of Previously Issued Consolidated Financial Statements (Tables)

12 Months Ended

Dec. 31, 2025

Revision of Previously Issued Consolidated Financial Statements [Abstract]

Revision of Previously Issued Consolidated Financial Statements

The following tables set forth the effects of the adjustment on affected items within the Company’s previously reported consolidated balance sheets for all impacted periods (in thousands):

	March 31, 2024
	As Previously Reported			Adjustment			As Revised

Goodwill	$	6,519		$	(822	)	$	5,697
Total assets	$	40,048		$	(822	)	$	39,226
Accrued expenses and other current liabilities	$	6,269		$	(824	)	$	5,445
Total current liabilities	$	12,588		$	(824	)	$	11,764
Total liabilities	$	30,616		$	(824	)	$	29,792
Accumulated deficit	$	(241,426	)	$	2		$	(241,424	)
Total stockholders’ equity	$	9,432		$	2		$	9,434
Total liabilities and stockholders’ equity	$	40,048		$	(822	)	$	39,226

	June 30, 2024
	As Previously Reported			Adjustment			As Revised

Goodwill	$	6,519		$	(822	)	$	5,697
Total assets	$	39,581		$	(822	)	$	38,759
Accrued expenses and other current liabilities	$	6,608		$	(832	)	$	5,776
Total current liabilities	$	12,133		$	(832	)	$	11,301
Total liabilities	$	30,085		$	(832	)	$	29,253
Accumulated deficit	$	(241,525	)	$	10		$	(241,515	)
Total stockholders’ equity	$	9,496		$	10		$	9,506
Total liabilities and stockholders’ equity	$	39,581		$	(822	)	$	38,759

	September 30, 2024
	As Previously Reported			Adjustment			As Revised

Goodwill	$	6,519		$	(822	)	$	5,697
Total assets	$	40,205		$	(822	)	$	39,383
Accrued expenses and other current liabilities	$	8,524		$	(881	)	$	7,643
Total current liabilities	$	14,046		$	(881	)	$	13,165
Total liabilities	$	30,862		$	(881	)	$	29,981
Accumulated deficit	$	(243,647	)	$	58		$	(243,589	)
Total stockholders’ equity	$	9,343		$	58		$	9,401
Total liabilities and stockholders’ equity	$	40,205		$	(822	)	$	39,383

	December 31, 2024
	As Previously Reported		Adjustment			As Revised

Goodwill	$	2,658	$	(1,229	)	$	1,429
Total assets	$	36,157	$	(1,229	)	$	34,928
Accrued expenses and other current liabilities	$	8,593	$	(1,229	)	$	7,364
Total current liabilities	$	14,625	$	(1,229	)	$	13,396
Total liabilities	$	31,185	$	(1,229	)	$	29,956
Total liabilities and stockholders’ equity	$	36,157	$	(1,229	)	$	34,928

	March 31, 2025
	As Previously Reported			Adjustment			As Revised

Goodwill	$	2,658		$	(1,229	)	$	1,429
Total assets	$	34,262		$	(1,229	)	$	33,033
Accrued expenses and other current liabilities	$	8,779		$	(1,539	)	$	7,240
Total current liabilities	$	15,139		$	(1,539	)	$	13,600
Total liabilities	$	31,593		$	(1,539	)	$	30,054
Accumulated deficit	$	(250,576	)	$	310		$	(250,266	)
Total stockholders’ equity	$	2,669		$	310		$	2,979
Total liabilities and stockholders’ equity	$	34,262		$	(1,229	)	$	33,033

	June 30, 2025
	As Previously Reported			Adjustment			As Revised

Goodwill	$	2,658		$	(1,229	)	$	1,429
Total assets	$	30,722		$	(1,229	)	$	29,493
Accrued expenses and other current liabilities	$	7,401		$	(1,453	)	$	5,948
Total current liabilities	$	14,004		$	(1,453	)	$	12,551
Total liabilities	$	30,414		$	(1,453	)	$	28,961
Accumulated deficit	$	(253,065	)	$	224		$	(252,841	)
Total stockholders’ equity	$	308		$	224		$	532
Total liabilities and stockholders’ equity	$	30,722		$	(1,229	)	$	29,493

	Three Months Ended March 31, 2024
	As Previously Reported			Adjustment			As Revised

General and administrative	$	2,710		$	(2	)	$	2,708
Total operating expenses	$	6,085		$	(2	)	$	6,083
Loss from operations	$	(2,889	)	$	2		$	(2,887	)
Net loss	$	(3,368	)	$	2		$	(3,366	)
Net loss per share of common stock, basic and diluted	$	(0.10	)	$	—		$	(0.10	)

	Three Months Ended June 30, 2024
	As Previously Reported			Adjustment			As Revised

General and administrative	$	2,210		$	(8	)	$	2,202
Total operating expenses	$	5,463		$	(8	)	$	5,455
Loss from operations	$	(486	)	$	8		$	(478	)
Net loss	$	(99	)	$	8		$	(91	)
Net loss per share of common stock, basic and diluted	$	(0.03	)	$	—		$	(0.03	)

	Six Months Ended June 30, 2024
	As Previously Reported			Adjustment			As Revised

General and administrative	$	4,920		$	(10	)	$	4,910
Total operating expenses	$	11,548		$	(10	)	$	11,538
Loss from operations	$	(3,375	)	$	10		$	(3,365	)
Net loss	$	(3,467	)	$	10		$	(3,457	)
Net loss per share of common stock, basic and diluted	$	(0.99	)	$	—		$	(0.99	)

	Three Months Ended September 30, 2024
	As Previously Reported			Adjustment			As Revised

General and administrative	$	3,669		$	(48	)	$	3,621
Total operating expenses	$	6,939		$	(48	)	$	6,891
Loss from operations	$	(1,653	)	$	48		$	(1,605	)
Net loss	$	(2,122	)	$	48		$	(2,074	)
Net loss per share of common stock, basic and diluted	$	(0.53	)	$	0.02		$	(0.51	)

	Nine Months Ended September 30, 2024
	As Previously Reported			Adjustment			As Revised

General and administrative	$	8,589		$	(58	)	$	8,531
Total operating expenses	$	18,487		$	(58	)	$	18,429
Loss from operations	$	(5,028	)	$	58		$	(4,970	)
Net loss	$	(5,589	)	$	58		$	(5,531	)
Net loss per share of common stock, basic and diluted	$	(1.52	)	$	0.02		$	(1.50	)

	Year Ended December 31, 2024
	As Previously Reported		Adjustment			As Revised

General and administrative	$	11,303	$	(407	)	$	10,896
Impairment of goodwill	$	3,861	$	407		$	4,268

	Three Months Ended March 31, 2025
	As Previously Reported			Adjustment			As Revised

General and administrative	$	2,573		$	(310	)	$	2,263
Total operating expenses	$	5,792		$	(310	)	$	5,482
Loss from operations	$	(2,015	)	$	310		$	(1,705	)
Net loss	$	(2,432	)	$	310		$	(2,122	)
Net loss per share of common stock, basic and diluted	$	(0.58	)	$	0.07		$	(0.51	)

	Three Months Ended June 30, 2025
	As Previously Reported			Adjustment			As Revised

General and administrative	$	2,911		$	86		$	2,997
Total operating expenses	$	6,530		$	86		$	6,616
Loss from operations	$	(2,224	)	$	(86	)	$	(2,310	)
Net loss	$	(2,489	)	$	(86	)	$	(2,575	)
Net loss per share of common stock, basic and diluted	$	(0.60	)	$	(0.02	)	$	(0.62	)

	Six Months Ended June 30, 2025
	As Previously Reported			Adjustment			As Revised

General and administrative	$	5,484		$	(224	)	$	5,260
Total operating expenses	$	12,322		$	(224	)	$	12,098
Loss from operations	$	(4,239	)	$	224		$	(4,015	)
Net loss	$	(4,921	)	$	224		$	(4,697	)
Net loss per share of common stock, basic and diluted	$	(1.18	)	$	0.05		$	(1.13	)

Stock-Based Compensation (Details) - USD ($)	12 Months Ended
Stock-Based Compensation (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
2016 Omnibus Incentive Plan [Member]
Stock-Based Compensation [Abstract]
Common stock reserved for future issuance (in Shares)	1,303,265
Number of shares available for issuance (in Shares)	536,826
Stock Options [Member]
Stock-Based Compensation [Abstract]
Weighted-average grant date fair value (in Dollars per share)	$ 1.84	$ 2.27
Unrecognized compensation expense	$ 800,000
Unrecognized compensation expense, weighted average period	2 years 6 months 10 days
Aggregate intrinsic value of options outstanding	$ 0	$ 8,000,000
Aggregate intrinsic value of options exercisable	0	0
Aggregate intrinsic value of options exercised	$ 0	$ 0
Expiration period	10 years
Restricted Stock Units [Member]
Stock-Based Compensation [Abstract]
Unvested (in Shares)	0	0	2,265
Unrecognized compensation expense	$ 0
Vested (in Shares)	0	2,265
Forfeited (in Shares)	0

Stock-Based Compensation - Restricted Stock Units (Details) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Stock-Based Compensation [Abstract]
Unvested balance at beginning of period (in Shares)	0	2,265
Unvested balance at beginning of period (in Dollars per share)	$ 0	$ 10.3
Vested (in Shares	0	(2,265)
Vested (in Dollars per share)		$ 10.3
Unvested balance at end of period (in Shares)	0	0
Unvested balance at end of period (in Dollars per share)		$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended					6 Months Ended		9 Months Ended	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2025	Jun. 30, 2024	Sep. 30, 2024	Dec. 31, 2025	Dec. 31, 2024
Pay vs Performance Disclosure
Net Income (Loss)	$ (2,575)	$ (2,122)	$ (2,074)	$ (91)	$ (3,366)	$ (4,697)	$ (3,457)	$ (5,531)	$ (6,261)	$ (10,086)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Organization and Nature of Business (Details) $ in Millions	12 Months Ended
Organization and Nature of Business (Details) $ in Millions	Dec. 31, 2025 USD ($)
At-the-Market Equity Offering [Member] \| Maximum [Member]
Organization and Nature of Business [Abstract]
Amount of additional common stock Company may sell under equity distribution agreement	$ 5.1

Stock-Based Compensation - Stock Option Activity (Details) - Stock Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Stock-Based Compensation [Abstract]
Outstanding at beginning of period (in Shares)	521,726	772,864
Outstanding at beginning of period (in Dollars per share)	$ 8.16	$ 11.07
Granted (in Shares)	238,000	70,000
Granted (in Dollars per share)	$ 2.55	$ 3.22
Forfeited and expired (in Shares)	(34,000)	(321,138)
Forfeited and expired (in Dollars per share)	$ 12.3	$ 14.07
Outstanding at end of period (in Shares)	725,726	521,726
Outstanding at end of period (in Dollars per share)	$ 6.13	$ 8.16
Outstanding	7 years 10 months 20 days	7 years 10 months 17 days
Exercisable at end of period (in Shares)	317,251
Exercisable at end of period (in Dollars per share)	$ 9.15
Exercisable	6 years 9 months 14 days
Vested and expected to vest (in Shares)	725,726
Vested and expected to vest (in Dollars per share)	$ 6.13
Vested and expected to vest	7 years 10 months 20 days

Property and Equipment, net (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 25, 2025	Sep. 30, 2025	Dec. 31, 2025	Dec. 31, 2025	Dec. 31, 2024
Property and Equipment, net [Abstract]
Property and equipment			$ 8,964	$ 8,964	$ 10,061
Settlement gains			$ 400	1,135	0
Depreciation and amortization expense				$ 2,900	$ 3,000
Settlement and Mutual Release Agreement [Member]
Property and Equipment, net [Abstract]
Payment to supplier		$ 100
Property and equipment		$ 800
Settlement gains	$ 700

Long-Term Debt

12 Months Ended

Dec. 31, 2025

Long-Term Debt [Abstract]

Long-Term Debt

10. Long-Term Debt

On September 30, 2021, the Company entered into a credit and security agreement with MidCap Financial Trust (“MidCap”), also acting as the administrative agent, and the lenders identified therein. The original terms provided for an $8.0 million senior term loan. Borrowings under the senior term loan originally bore interest at LIBOR (with a LIBOR floor rate of 0.50%) plus 7.50% per year and were scheduled to mature on September 1, 2026, unless terminated earlier. The Company was obligated to make monthly interest-only payments through September 30, 2024. The credit and security agreement was amended on January 10, 2022 to provide MidCap’s consent to the TheraClear asset acquisition. On September 6, 2022, the Company amended the facility to transition, upon the cessation of LIBOR, to bear interest at one-month Secured Overnight Financing Rate (“SOFR”), or such other applicable period, plus 0.10%, with a floor of 0.50%.

On June 30, 2023, the Company entered into (a) Amendment No. 3 to the credit and security agreement (the “Third Amendment”); (b) the Amended and Restated Warrant Agreement (the “A&R Warrant”) with MidCap Funding XXVII Trust (together with any registered holder from time to time or any holder of the shares issuable or issued upon the exercise or conversion of the warrant, the “Warrantholder”), which amended and restated the warrant agreement to purchase shares of the common stock of the Company, dated as of September 30, 2021 (the “Prior Warrant”), with the Warrantholder; (c) the Amended and Restated Registration Rights Agreement (the “A&R Registration Rights Agreement”) with the Warrantholder, which amended and restated the registration rights agreement, dated as of September 30, 2021, with the Warrantholder; and (d) a letter agreement (the “Fee Letter Agreement”) with MidCap, as agent.

On February 20, 2024, the Company entered into (a) Amendment No. 4 to the credit and security agreement (the “Fourth Amendment”), which amended the credit and security agreement, and (b) a second amended and restated letter agreement (“Amended Fee Letter Agreement”) with MidCap, as agent.

On March 27, 2024, the Company entered into Amendment No. 5 to the credit and security agreement (the “Fifth Amendment”), which further amended the credit and security agreement to clarify certain provisions related to the maintenance of cash collateral accounts.

On November 12, 2025, the Company entered into Amendment No. 6 to the credit and security agreement (the “Sixth Amendment” and, as amended to date, the “Senior Term Facility”). The Sixth Amendment provides, among other things, that there shall be no measurement of net revenue for purposes of calculating financial covenant compliance for the quarterly period ended September 30, 2025, and continuing thereafter through the quarterly period ending September 30, 2026 (the “Pause Period”). The Sixth Amendment further provides that commencing with the first quarterly period ending after September 30, 2026, and for each quarterly period thereafter, the Company shall not permit net revenue for any applicable quarterly period, as tested quarterly on the last day of the applicable quarter to be less than the minimum revenue required by the credit and security agreement for such quarter.

The Senior Term Facility provides for a senior secured term loan facility of up to $20.0 million, of which $8.0 million was drawn by the Company on September 30, 2021 (“Credit Facility #1”), $7.0 million was drawn by the Company on June 30, 2023 (“Credit Facility #2”), and an additional $5.0 million tranche (“Credit Facility #3”) was available to be drawn by the Company if its Dermatology Recurring Procedures Revenue (as defined in the Senior Term Facility) for the preceding 12 calendar months (ending on the last day of the calendar month for which a compliance certificate is delivered) was greater than or equal to $30.0 million (such condition, the “Applicable Funding Condition”). The Company did not meet the Applicable Funding Condition and Credit Facility #3 is no longer available to the Company. All borrowings are secured by substantially all of the Company’s assets.

Borrowings under the Senior Term Facility bear interest at a rate per annum equal to the sum of (a) the greater of (i) the sum of (A) 30-day forward-looking term rate of one month SOFR, as published by CME Group Benchmark Administration Limited, from time to time, plus (B) 0.10%, and (ii) the applicable floor rate of 3.50%, with such sum reset monthly, and (b) 7.50%. The effective interest rate of the Senior Term Facility as of December 31, 2025 and 2024 was 12.48% and 13.16%, respectively. The Company is obligated to make interest-only payments (payable monthly in arrears) through June 1, 2026. Commencing on July 1, 2026 and continuing for the remaining 24 months of the facility, the Company will be required to make monthly interest payments and monthly principal payments based on a straight-line amortization schedule set forth in the Senior Term Facility, subject to certain adjustments as described in the Senior Term Facility. The final maturity date under the Senior Term Facility is June 1, 2028, unless earlier terminated. The Senior Term Facility requires the Company to dedicate 100% of certain insurance proceeds to the prepayment of the outstanding term loan, subject to certain exceptions and net of certain expenses and repayments.

The Company may voluntarily prepay the outstanding term loan under the Senior Term Facility, with such prepayment in an amount of at least $5.0 million, at any time upon 30 days’ written notice. Upon prepayment, the Company will be required to pay a prepayment fee equal to (i) 2.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 24 months and 36 months after February 20, 2024, or (ii) 1.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made after 36 months after February 20, 2024 and prior to the maturity date.

The Senior Term Facility contains certain customary representations and warranties, affirmative covenants and conditions, as well as various negative covenants. Further, the Senior Term Facility contains (a) a quarterly financial covenant that requires the Company to not have less than $33.0 million of net revenue for the trailing 12-month period as of December 31, 2026 and, for periods ending after December 31, 2026, such net revenue as determined in good faith by MidCap, which shall not be less than the applicable minimum net revenue amount for the immediately preceding period and $33.0 million, and (b) a minimum of unrestricted cash (as defined in the Senior Term Facility), at all times, of not less than $3.0 million. As of December 31, 2025, there were no financial covenants in effect under the Senior Term Facility due to the Pause Period provided by the Sixth Amendment.

Upon the occurrence and during the continuance of an event of default, MidCap may, and at the direction of a requisite percentage of the lenders must, (i) suspend or terminate the term loan commitment and MidCap and the other lenders’ obligations with respect thereto, and (ii) by notice to the Company, declare all or any portion of the obligations under the Senior Term Facility to be immediately due and payable. In addition to MidCap’s other rights and available remedies, but subject to applicable cure periods, upon the occurrence and during the continuance of an event of default, MidCap may, and at the direction of a requisite percentage of the lenders must, terminate the Senior Term Facility. As discussed in Note 1. Organization and Nature of Business, the Company’s common stock was delisted from The Nasdaq Capital Market in February 2026, which is an event of default under the Senior Term Facility. The event of default has not been cured as of the date of issuance of these consolidated financial statements and, accordingly, the Company has classified the entire outstanding principal balance as a current liability in the consolidated balance sheet as of December 31, 2025.

Pursuant to the Amended Fee Letter Agreement, the Company agreed to pay MidCap, as administrative agent, the following fees: (a) an origination fee on June 30, 2023 in an amount equal to (i) the Credit Extensions (as defined in the Senior Term Facility) in respect of Credit Facility #2, multiplied by (ii) 0.50%; (b) on the maturity date of the Senior Term Facility or any earlier date on which the obligations thereunder become due and payable in full or are otherwise paid in full (such date, the “Full Exit Fee Payment Date”), the Company shall pay an exit fee equal to (i) 4.00% of the total aggregate principal amount of Credit Extensions (as defined in the Senior Term Facility) made pursuant to the Senior Term Facility (regardless of any repayment or prepayment thereof) as of the Full Exit Fee Payment Date (such aggregate amount, the “Exit Fee Base Amount”), less (ii) any Partial Exit Fee (as defined below) previously paid; (c) on the date of any voluntary or mandatory partial prepayment of the borrowings under the Senior Term Facility (or on the date such mandatory prepayment becomes due and payable) (each such date, a “Partial Exit Fee Payment Date”), the Company shall pay an exit fee equal to 4.00% of the principal amount of the credit facilities paid or prepaid (or required to be paid in the case of a mandatory prepayment) as of the Partial Exit Fee Payment Date (such amount, the “Partial Exit Fee”); and (d) an origination fee payable contemporaneously with funding Credit Facility #3 in an amount equal to (i) the Credit Extensions (as defined in the Senior Term Facility) in respect of Credit Facility #3, multiplied by (ii) 0.50%.

The Prior Warrant allowed the Warrantholder, an affiliate of the lender, to purchase 37,362 shares of the Company’s common stock at an exercise price equal to $18.20 per share for a 10-year period ending September 30, 2031. Pursuant to, and in accordance with, the terms and conditions of the A&R Warrant, which amended and restated the Prior Warrant, the Warrantholder can purchase 80,000 shares of the Company’s common stock at an exercise price equal to $8.80 per share for a 10-year period ending on June 30, 2033. Pursuant to the A&R Registration Rights Agreement, the Company registered the shares underlying the A&R Warrant effective August 18, 2023. The amendment of the warrant resulted in an increase in the fair value of the warrant, which was accounted for as a lender fee.

The Fourth Amendment was accounted for as a debt modification, as the new loan is not considered substantially different from the existing loan. In connection with the Fourth Amendment, the Company increased the accrued exit fee, which is recorded as both a debt discount and an increase to the principal amount of debt, to $0.6 million. The debt discount, which also includes third party costs incurred in connection with the Third Amendment of $13.0 thousand, is being recognized as interest expense over the term of the Senior Term Facility using the effective-interest method. The unamortized debt discount was $0.3 million and $0.4 million as of December 31, 2025 and 2024, respectively. The Company recognized interest expense of $2.0 million during the year ended December 31, 2025, of which $0.2 million was related to the amortization of the debt discount. The Company recognized interest expense of $2.1 million during the year ended December 31, 2024, of which $0.1 million was related to the amortization of the debt discount.

Future minimum principal payments at December 31, 2025 are as follows (in thousands):

Years ending December 31:
2026	$	15,000
		15,000
Exit fee		600
		15,600
Less: unamortized debt discount		(251	)
		15,349
Less: current portion of long-term debt		(15,349	)
Long-term debt, net	$	—

Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Revenues, net	$ 30,696	$ 33,562
Dermatology Recurring Procedures [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Revenues, net	21,478	21,171
Dermatology Procedures Equipment [Member]
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Revenues, net	$ 9,218	$ 12,391

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Long-Term Debt - Future Minimum Principal Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Long-Term Debt [Abstract]
2026	$ 15,000
Total	15,000
Exit fee	600
Long term debt after exit fee	15,600
Less: unamortized debt discount	(251)
Long-term debt	15,349
Less: current portion of long-term debt	(15,349)	$ 0
Long-term debt, net	$ 0	$ 15,192

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-4

+ Details

Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	Sep. 25, 2025	Dec. 31, 2025	Dec. 31, 2025	Dec. 31, 2024	Oct. 31, 2025
Intangible Assets and Goodwill [Abstract]
Intangible asset carrying value		$ 3,377	$ 3,377	$ 5,348
Settlement gains		400	1,135	0
Amortization expense of intangible assets			1,200	2,000
Impairment of goodwill			0	4,268
Settlement and Mutual Release Agreement [Member]
Intangible Assets and Goodwill [Abstract]
Contingent consideration derecognized		(1,200)
Settlement gains	$ 700
Product Technology [Member]
Intangible Assets and Goodwill [Abstract]
Intangible asset carrying value		$ 0	0	824	$ 700
Dermatology Recurring Procedures [Member]
Intangible Assets and Goodwill [Abstract]
Impairment of goodwill			$ 0	$ 4,300

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-29

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-29

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 24: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 26: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 27: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 28: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-3

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details

- Definition

Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References + Details

Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
Accrued Expenses and Other Current Liabilities [Abstract]
State sales, use and other taxes	$ 3,757			$ 5,142
Compensation and related benefits	1,913			1,781
Warranty obligations	157			213
Professional fees and other	328			228
Accrued expenses and other current liabilities	$ 6,155	$ 5,948	$ 7,240	$ 7,364	$ 7,643	$ 5,776	$ 5,445

Leases (Details) - USD ($) $ in Millions	12 Months Ended
Leases (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Leases [Abstract]
Extended lease term	5 years
Increase in ROU asset and operating lease liability resulting from lease modification	$ 0.0	$ 1.0
Operating lease costs	0.5	0.5
Cash paid for amounts included in measurement of operating lease liabilities	$ 0.5	$ 0.5
Weighted average incremental borrowing rate	12.70%	12.18%
Weighted average remaining lease term	3 years 7 months 6 days	4 years 1 month 6 days
Minimum [Member]
Leases [Abstract]
Remaining lease term	1 year
Maximum [Member]
Leases [Abstract]
Remaining lease term	4 years

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2025

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

9. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	December 31,
	2025		2024

State sales, use and other taxes	$	3,757	$	5,142
Compensation and related benefits		1,913		1,781
Warranty obligations		157		213
Professional fees and other		328		228
	$	6,155	$	7,364

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2025	Mar. 16, 2026	Jun. 30, 2025
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	true
Document Financial Statement Restatement Recovery Analysis [Flag]	false
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Amendment Flag	false
Document Period End Date	Dec. 31, 2025
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	FY
Entity Information [Line Items]
Entity Registrant Name	STRATA SKIN SCIENCES, INC.
Entity Central Index Key	0001051514
Entity File Number	0-11635
Entity Tax Identification Number	13-3986004
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	Yes
Entity Current Reporting Status	No
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 3,699,213
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	5 Walnut Grove Drive
Entity Address, Address Line Two	Suite 140
Entity Address, City or Town	Horsham
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19044
Entity Phone Fax Numbers [Line Items]
City Area Code	215
Local Phone Number	619-3200
Entity Listings [Line Items]
Entity Common Stock, Shares Outstanding		5,888,199

Inventories - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Inventories [Abstract]
Raw materials and work-in-process	$ 2,601	$ 2,041
Finished goods	213	205
Inventories, net	$ 2,814	$ 2,246

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2025
Stockholders’ Equity [Abstract]
Stockholders' Equity	12. Stockholders’ Equity Preferred Stock The Company is authorized to issue preferred stock with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. Other than the limitations on conversions to keep each such holder’s beneficial ownership below 9.99%, the terms of the Series C convertible preferred stock generally bestow the same rights to each holder as such holder would receive if they were common stock shareholders and are not redeemable by the holders, except that the Series C convertible preferred stock shares do not have voting rights. Each share of Series C convertible preferred stock has a stated value of $1.0 thousand and is convertible into shares of common stock at a conversion price equal to $26.90. No preferred shares were outstanding as of December 31, 2025 and 2024. Common Stock No shares were issued upon the vesting of restricted stock during the years ended December 31, 2025 and 2024. In October 2021, the Company entered into an equity distribution agreement under which the Company could sell up to $11.0 million of its shares of common stock in registered “at-the-market” offerings. The shares were offered at prevailing market prices, and the Company paid commissions of up to 3.0% of the gross proceeds from the sale of shares sold through the Company’s agent, which may act as an agent and/or principal. In July 2024, the Company sold 665,136 shares of its common stock under the equity distribution agreement at an average purchase price of $3.16 per share for total gross and net proceeds of $2.1 million and $1.9 million, respectively. In September 2025, the Company sold 1,097,547 shares of its common stock under the equity distribution agreement at an average price of $2.20 per share for total gross and net proceeds of $2.4 million and $2.2 million, respectively. In October 2025, the Company sold an aggregate of 619,491 shares of its common stock under the equity distribution agreement at an average price of $2.30 per share for total gross and net proceeds of $1.4 million. As of December 31, 2025, the Company could sell up to an additional $5.1 million of its shares of common stock under the equity distribution agreement, subject to certain limitations. As of the date that the consolidated financial statements were issued, the Company may not sell any of its shares of common stock under the equity distribution agreement because it deregistered the unsold shares following the delisting of its common stock. Common Stock Warrants In September 2021 and in connection with entering into the Company’s Senior Term Facility (Note 10), the Company issued a warrant to purchase 37,362 shares of the Company’s common stock at an initial exercise price of $18.20 per share. The warrant was amended in June 2023 in connection with the execution of the Third Amendment to the Senior Term Facility. The amended warrant is to purchase 80,000 shares of the Company’s common stock at an exercise price equal to $8.80 per share. The warrant is equity classified and is exercisable at any time on or prior to the tenth anniversary of its amendment date. As of December 31, 2025, the warrant remains outstanding in its entirety.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Property and Equipment, net - Components of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Property and Equipment, net [Abstract]
Property and equipment, gross	$ 37,531	$ 36,209
Less: accumulated depreciation and amortization	(28,567)	(26,148)
Property and equipment, net	8,964	10,061
Lasers Placed-In-Service [Member]
Property and Equipment, net [Abstract]
Property and equipment, gross	34,725	33,489
Equipment, Computer Hardware and Software [Member]
Property and Equipment, net [Abstract]
Property and equipment, gross	300	300
Furniture and Fixtures [Member]
Property and Equipment, net [Abstract]
Property and equipment, gross	240	240
Leasehold Improvements [Member]
Property and Equipment, net [Abstract]
Property and equipment, gross	77	87
Lasers-In-Process [Member]
Property and Equipment, net [Abstract]
Property and equipment, gross	$ 2,189	$ 2,093

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2025
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events The Company evaluated subsequent events and transactions that occurred after the consolidated balance sheet date up to the date that the consolidated financial statements were issued. As previously disclosed on August 22, 2025, the Company received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2.5 million (the “Stockholders’ Equity Requirement”). On September 19, 2025, the Company submitted a plan to Nasdaq to regain compliance with the Stockholders’ Equity Requirement (the “Plan”). In response to the Plan, on October 13, 2025, Nasdaq provided the Company notice that Nasdaq had accepted the Plan and granted the Company an extension until February 16, 2026 to regain compliance with the Stockholders’ Equity Requirement. On February 9, 2026, the Company notified Nasdaq that it would not be able to satisfy the terms of the provided extension. As a result, on February 10, 2026, Nasdaq provided the Company notice that, unless it requested an appeal of the determination related to the Stockholders’ Equity Requirement, trading of its common stock would be suspended at the opening of business on February 19, 2026, and a Form 25-NSE would be filed with the SEC, which would remove its securities from listing and registration on The Nasdaq Capital Market. Pursuant to the foregoing, on February 19, 2026, the Company filed Form 15 removing its common stock from registration on The Nasdaq Capital Market. The Company’s shares of common stock are now quoted OTC. Additionally, the Company filed Certification and Notice of Termination of Registration under Section 12(g) of the Securities and Exchange Act of 1934. Pursuant to this filing, the Company has terminated its obligations to file periodic reports such as the 10-K and 10-Q with the SEC. Subsequent events related to the delisting of the Company’s common stock have also been disclosed in Notes 1. Organization and Nature of Business and 10. Long-Term Debt. No other subsequent events have been identified that would have required adjustment or disclosure in the consolidated financial statements.

Basis of Presentation and Summary of Significant Accounting Policies - Allowance for Credit Losses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Balance, beginning of year	$ 433	$ 222
Balance, end of year	551	433
Provision for expected losses	134	(179)
Write-offs charged against the allowance	(16)	141
Other adjustments	$ 0	$ 249

Basis of Presentation and Summary of Significant Accounting Policies - Future Undiscounted Fixed Treatment Code Payments from International Dermatology Recurring Procedures (Details) - Dermatology Recurring Procedures [Member] $ in Thousands	Dec. 31, 2025 USD ($)
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 5,283
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Expected timing of satisfaction period	1 year
Future undiscounted fixed payments from international recurring revenue customers	$ 1,983
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Expected timing of satisfaction period	1 year
Future undiscounted fixed payments from international recurring revenue customers	$ 1,798
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Expected timing of satisfaction period	1 year
Future undiscounted fixed payments from international recurring revenue customers	$ 1,236
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2029-01-01
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Expected timing of satisfaction period	1 year
Future undiscounted fixed payments from international recurring revenue customers	$ 266

Stock-Based Compensation

12 Months Ended

Dec. 31, 2025

Stock-Based Compensation [Abstract]

Stock-Based Compensation

13. Stock-Based Compensation

The Company’s 2016 Omnibus Incentive Stock Plan (“2016 Plan”), as amended, has reserved up to 1,303,265 shares of common stock for future issuance. As of December 31, 2025, there were 536,826 shares of common stock remaining available for issuance for awards under the 2016 Plan.

	Year Ended December 31,
	2025		2024

Selling and marketing	$	100	$	7
General and administrative		543		420
	$	643	$	427

Stock Options

The following table summarizes stock option activity for the years ended December 31, 2025 and 2024:

	Number of Shares Under Option Plan			Weighted-Average Exercise Price per Option		Weighted-Average Remaining Contractual Term (in years)

Outstanding at January 1, 2024		772,864		$	11.07
Granted		70,000		$	3.22
Forfeited and expired		(321,138	)	$	14.07
Outstanding at December 31, 2024		521,726		$	8.16		7.88
Granted		238,000		$	2.55
Forfeited and expired		(34,000	)	$	12.30
Outstanding at December 31, 2025		725,726		$	6.13		7.89
Exercisable at December 31, 2025		317,251		$	9.15		6.79
Vested and expected to vest at December 31, 2025		725,726		$	6.13		7.89

The weighted‑average grant date fair value of options granted was $1.84 and $2.27 per share during the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, the total unrecognized compensation expense related to unvested stock option awards was $0.8 million, which the Company expects to recognize over a weighted‑average period of approximately 2.53 years. The aggregate intrinsic value of options outstanding at December 31, 2024 was $8.0 thousand. There was no aggregate intrinsic value of options outstanding at December 31, 2025. Further, there was no aggregate intrinsic value of options exercisable and no options were exercised during the years ended December 31, 2025 and 2024.

The fair value of options is estimated using the Black-Scholes option pricing model which takes into account inputs such as the exercise price, the value of the underlying common stock at the grant date, expected term, expected volatility, risk free interest rate and dividend yield. The fair value of each grant of options during the years ended December 31, 2025 and 2024 was determined using the methods and assumptions discussed below.

•

The expected term of employee options is based on the observed and expected time to full-vesting, forfeiture and exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. Options expire up to a maximum of ten years from the date of grant.

•

The expected volatility is based on historical volatility of the Company’s common stock.

•

The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.

•

The expected dividend yield is none because the Company has not historically paid and does not expect for the foreseeable future to pay a dividend on its shares of common stock.

	Year Ended December 31,
	2025			2024

Expected term (in years)		6.5			6.46
Expected volatility		77.58	%		77.93	%
Risk-free rate		4.26	%		3.91	%
Dividend yield		0.00	%		0.00	%

Restricted Stock Units

Restricted stock units have historically been issued to certain board members. Activity in restricted stock units is summarized in the following table:

	Number of Units			Weighted-Average Grant Date Fair Value

Unvested at January 1, 2024		2,265		$	10.30
Vested		(2,265	)	$	10.30
Unvested at December 31, 2024		—		$	—

As of December 31, 2025, there were no unvested restricted stock units and there was no unrecognized compensation expense related to restricted stock units. No restricted stock units were granted, vested or forfeited during the year ended December 31, 2025.

Property and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2025

Property and Equipment, net [Abstract]

Components of Property and Equipment

Property and equipment consist of the following (in thousands):

	December 31,
	2025			2024

Lasers placed-in-service	$	34,725		$	33,489
Equipment, computer hardware and software		300			300
Furniture and fixtures		240			240
Leasehold improvements		77			87
Lasers-in-process		2,189			2,093
		37,531			36,209
Less: accumulated depreciation and amortization		(28,567	)		(26,148	)
	$	8,964		$	10,061

Inventories

12 Months Ended

Dec. 31, 2025

Inventories [Abstract]

Inventories

5. Inventories

Inventories consist of the following (in thousands):

	December 31,
	2025		2024

Raw materials and work-in-process	$	2,601	$	2,041
Finished goods		213		205
	$	2,814	$	2,246

Due to the expiration of extended warranty service contracts that were assumed in August 2021 in connection with the acquisition of Pharos laser system products, the Company wrote off $0.2 million of inventories that were no longer needed for warranty purposes during the year ended December 31, 2024, which is included in cost of revenues in the consolidated statement of operations.

Stock-Based Compensation - Weighted Average Assumption Used for Grant Date Fair Value of Option Grants (Details)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Stock-Based Compensation [Abstract]
Expected term (in years)	6 years 6 months	6 years 5 months 15 days
Expected volatility	77.58%	77.93%
Risk-free rate	4.26%	3.91%
Dividend rate	0.00%	0.00%

Leases - Operating Lease Maturities (Details) $ in Thousands	Dec. 31, 2025 USD ($)
Leases [Abstract]
2026	$ 334
2027	290
2028	301
2029	232
Total remaining lease payments	1,157
Less: imputed interest	(238)
Total lease liabilities	$ 919

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Income Taxes [Abstract]
Loss before income taxes	$ (6,249)	$ (10,256)
Valuation allowance - Deferred tax asset change in amount	3,300
Unrecognized tax benefits	$ 0	$ 0

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Intangible Assets and Goodwill - Components of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Oct. 31, 2025	Dec. 31, 2024
Intangible Assets and Goodwill [Abstract]
Gross carrying value	$ 21,414		$ 24,222
Accumulated amortization	(18,037)		(18,874)
Net book value	3,377		5,348
Core Technology [Member]
Intangible Assets and Goodwill [Abstract]
Gross carrying value	5,700		5,700
Accumulated amortization	(5,700)		(5,415)
Net book value	0		285
Product Technology [Member]
Intangible Assets and Goodwill [Abstract]
Gross carrying value	2,000		4,808
Accumulated amortization	(2,000)		(3,984)
Net book value	0	$ 700	824
Customer Relationships [Member]
Intangible Assets and Goodwill [Abstract]
Gross carrying value	6,900		6,900
Accumulated amortization	(6,900)		(6,555)
Net book value	0		345
Tradenames [Member]
Intangible Assets and Goodwill [Abstract]
Gross carrying value	1,500		1,500
Accumulated amortization	(1,500)		(1,425)
Net book value	0		75
Pharos Customer Lists [Member]
Intangible Assets and Goodwill [Abstract]
Gross carrying value	5,314		5,314
Accumulated amortization	(1,937)		(1,495)
Net book value	$ 3,377		$ 3,819

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Intangible Assets and Goodwill - Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Dec. 31, 2025 USD ($)
Intangible Assets and Goodwill [Abstract]
2026	$ 443
2027	443
2028	443
2029	443
2030	$ 443

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2025
Auditor [Table]
Auditor Name	CBIZ CPAs P.C.
Auditor Firm ID	199
Auditor Location	Philadelphia, Pennsylvania

Long-Term Debt (Details)		1 Months Ended		12 Months Ended
Long-Term Debt (Details)	Sep. 06, 2022	Jun. 30, 2023 $ / shares shares	Sep. 30, 2021 $ / shares shares	Dec. 31, 2025 USD ($) Payment $ / shares shares	Dec. 31, 2024 USD ($)
Long-Term Debt [Abstract]
Exit fee				$ 600,000
Unamortized debt discount				251,000
SOFR [Member]
Long-Term Debt [Abstract]
Interest rate floor	0.50%
Basis spread on variable rate	0.10%
Term of variable rate	1 month
Senior Term Facility [Member]
Long-Term Debt [Abstract]
Warrants issued (in Shares) \| shares		80,000	37,362
Warrants, exercise price (in Dollars per share) \| $ / shares		$ 8.8	$ 18.2
Senior Term Facility [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Face amount of debt				$ 8,000,000
Maturity date				Sep. 01, 2026
Frequency of payment				monthly
Number of monthly principal payments plus interest (in Payment) \| Payment				24
Notice period				30 days
Prepayment fee if prepayment is made between twenty-four months and thirty-six months				2.00%
Prepayment fee if prepayment is made after thirty-six months				1.00%
Minimum net revenue threshold by trailing 12-month period				$ 33,000,000
Minimum net revenue threshold by December 31, 2026				33,000,000
Minimum unrestricted cash				3,000,000
Interest expense				2,000,000	$ 2,100,000
Amortization of debt discount				$ 200,000	$ 100,000
Senior Term Facility [Member] \| LIBOR [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Interest rate floor				0.50%
Basis spread on variable rate				7.50%
Senior Term Facility [Member] \| Common Stock [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Warrants issued (in Shares) \| shares				37,362
Warrants, exercise price (in Dollars per share) \| $ / shares				$ 18.2
Warrants, expected term				10 years
Senior Term Facility, Amendment [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Face amount of debt				$ 20,000,000
Interest rate floor				3.50%
Amount available to be drawn under condition				$ 30,000,000
Forward looking term				30 days
Effective interest rate				12.48%	13.16%
Required percentage of certain insurance proceeds				100.00%
Senior Term Facility, Amendment [Member] \| SOFR [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Basis spread on variable rate				7.50%
Term of variable rate				1 month
Base interest rate				0.10%
Credit Facility #1 [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Amount drawn				$ 8,000,000
Credit Facility #2 [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Amount drawn				$ 7,000,000
Percentage of administrative agent fess				0.50%
Percentage of credit extension				4.00%
Credit Facility #3 [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Amount available for amount drawn				$ 5,000,000
Percentage of credit extension				0.50%
Percentage of exit fee				4.00%
Senior Term Facility, Fourth Amendment [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Exit fee				$ 600,000
Senior Term Facility, Third Amendment [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Third party costs incurred				13,000
Unamortized debt discount				$ 300,000	$ 400,000
A&R Warrant [Member] \| Senior Term Facility [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Warrants issued (in Shares) \| shares				80,000
Warrants, exercise price (in Dollars per share) \| $ / shares				$ 8.8
Warrants, expected term				10 years
Minimum [Member] \| Senior Term Facility [Member] \| MidCap Financial Trust [Member]
Long-Term Debt [Abstract]
Prepayment of debt				$ 5,000,000

Income Taxes - Cash Paid for Income Taxes, Net of Refunds Received (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Taxes [Abstract]
Federal	$ 0	$ 0
Texas [Member]
Income Taxes [Abstract]
Texas	9	10
Cash paid for income taxes, net of refunds received	$ 9	$ 10

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Consolidated Balance Sheets [Abstract]
Allowance for credit losses	$ 551	$ 433
Series C Convertible Preferred Stock, par value (in Dollars per share)	$ 0.1	$ 0.1
Series C Convertible Preferred Stock, shares authorized (in Shares)	10,000,000	10,000,000
Series C Convertible Preferred Stock, shares issued (in Shares)	0	0
Series C Convertible Preferred Stock, shares outstanding (in Shares)	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in Shares)	150,000,000	150,000,000
Common stock, shares issued (in Shares)	5,888,199	4,171,161
Common stock, shares outstanding (in Shares)	5,888,199	4,171,161

Intangible Assets and Goodwill

12 Months Ended

Dec. 31, 2025

Intangible Assets and Goodwill [Abstract]

Intangible Assets and Goodwill

8. Intangible Assets and Goodwill

Intangible assets consist of the following (in thousands):

December 31, 2025	Gross Carrying Value		Accumulated Amortization			Net Book Value

Core technology	$	5,700	$	(5,700	)	$	—
Product technology		2,000		(2,000	)		—
Customer relationships		6,900		(6,900	)		—
Tradenames		1,500		(1,500	)		—
Pharos customer lists		5,314		(1,937	)		3,377
	$	21,414	$	(18,037	)	$	3,377

December 31, 2024	Gross Carrying Value		Accumulated Amortization			Net Book Value

Core technology	$	5,700	$	(5,415	)	$	285
Product technology		4,808		(3,984	)		824
Customer relationships		6,900		(6,555	)		345
Tradenames		1,500		(1,425	)		75
Pharos customer lists		5,314		(1,495	)		3,819
	$	24,222	$	(18,874	)	$	5,348

In October 2025, the Company entered into a Settlement and Mutual Release Agreement (“Theravant Settlement”) with Theravant, from which it purchased the TheraClear devices in 2022, pursuant to which the Company was released from its outstanding obligations for contingent consideration. In the fourth quarter of 2025, the Company derecognized its liability for contingent consideration of $1.2 million and wrote off the related product technology intangible asset, which had a carrying value of $0.7 million. The transaction resulted in the recognition of a gain of $0.4 million, which is reflected within settlement gains in the consolidated statement of operations.

The Company recorded amortization expense of $1.2 million and $2.0 million during the years ended December 31, 2025 and 2024, respectively.

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years (in thousands):

Years ending December 31:
2026	$	443
2027	$	443
2028	$	443
2029	$	443
2030	$	443

Goodwill consists of the following (in thousands):

	December 31,
	2025		2024

Dermatology recurring procedures segment	$	584	$	584
Dermatology procedures equipment segment		845		845
	$	1,429	$	1,429

The Company recognized no goodwill impairment charge during the year ended December 31, 2025, and a goodwill impairment charge of $4.3 million during the year ended December 31, 2024 related to the dermatology recurring procedures segment primarily driven by a decline in projected cash flows, including revenues and profitability (see Note 2).

Business and Geographical Reporting Segments - Segment Reporting Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended	12 Months Ended
	Dec. 31, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2025	Jun. 30, 2024	Sep. 30, 2024	Dec. 31, 2025	Dec. 31, 2024
Business and Geographical Reporting Segments [Abstract]
Revenues, net										$ 30,696	$ 33,562
Cost of revenues										12,815	14,340
Gross profit										$ 17,881	$ 19,222
Gross profit %										58.30%	57.30%
Allocated expenses:
Engineering and product development										$ 421	$ 883
Selling and marketing										13,111	12,430
Impairment of goodwill										0	4,268
Unallocated expenses											10,896
General and administrative		$ 2,997	$ 2,263	$ 3,621	$ 2,202	$ 2,708	$ 5,260	$ 4,910	$ 8,531	10,184	10,896
Settlement gains	$ (400)									(1,135)	0
Total operating expenses		6,616	5,482	6,891	5,455	6,083	12,098	11,538	18,429	22,581	28,477
(Loss) income from operations		$ (2,310)	$ (1,705)	$ (1,605)	$ (478)	$ (2,887)	$ (4,015)	$ (3,365)	$ (4,970)	(4,700)	(9,255)
Interest expense										(1,959)	(2,107)
Interest income										410	242
Other income										0	864
Income (loss) before (provision for) benefit from income taxes										(6,249)	(10,256)
Dermatology Recurring Procedures [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues, net										21,478	21,171
Allocated expenses:
Impairment of goodwill										0	4,300
Dermatology Procedures Equipment [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues, net										9,218	12,391
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues, net										21,478	21,171
Cost of revenues										8,164	7,799
Gross profit										$ 13,314	$ 13,372
Gross profit %										62.00%	63.20%
Allocated expenses:
Engineering and product development										$ 305	$ 658
Selling and marketing										11,102	11,140
Impairment of goodwill											4,268
Unallocated expenses											0
General and administrative										0
Settlement gains										0
Total operating expenses										11,407	16,066
(Loss) income from operations										1,907	(2,694)
Interest expense										0	0
Interest income										0	0
Other income											0
Income (loss) before (provision for) benefit from income taxes										1,907	(2,694)
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Business and Geographical Reporting Segments [Abstract]
Revenues, net										9,218	12,391
Cost of revenues										4,651	6,541
Gross profit										$ 4,567	$ 5,850
Gross profit %										49.50%	47.20%
Allocated expenses:
Engineering and product development										$ 116	$ 225
Selling and marketing										2,009	1,290
Impairment of goodwill											0
Unallocated expenses											0
General and administrative										0
Settlement gains										0
Total operating expenses										2,125	1,515
(Loss) income from operations										2,442	4,335
Interest expense										0	0
Interest income										0	0
Other income											0
Income (loss) before (provision for) benefit from income taxes										$ 2,442	$ 4,335

Property and Equipment, net

12 Months Ended

Dec. 31, 2025

Property and Equipment, net [Abstract]

Property and Equipment, net

6. Property and Equipment, net

Property and equipment consist of the following (in thousands):

	December 31,
	2025			2024

Lasers placed-in-service	$	34,725		$	33,489
Equipment, computer hardware and software		300			300
Furniture and fixtures		240			240
Leasehold improvements		77			87
Lasers-in-process		2,189			2,093
		37,531			36,209
Less: accumulated depreciation and amortization		(28,567	)		(26,148	)
	$	8,964		$	10,061

During September 2025, the Company entered into a settlement and mutual release agreement with a supplier to resolve outstanding obligations related to the manufacture of property and equipment. Under the terms of the settlement, the Company paid $0.1 million for approximately $0.8 million of property and equipment, and both parties were released from any and all claims, asserted or unasserted, arising from the related purchase order and service agreement. The transaction resulted in the recognition of a gain of $0.7 million, which is reflected within settlement gains in the accompanying consolidated statements of operations.

The Company recorded depreciation and amortization expense of $2.9 million and $3.0 million during the years ended December 31, 2025 and 2024, respectively.

Business and Geographical Reporting Segments

12 Months Ended

Dec. 31, 2025

Business and Geographical Reporting Segments [Abstract]

Business and Geographical Reporting Segments

15. Business and Geographical Reporting Segments

The Company has organized its business into two operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC and TheraClear procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense) is also not allocated to the operating segments.

The following tables present results of operations from the Company’s business segments for the periods indicated below (in thousands, except gross profit %):

Year Ended December 31, 2025	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total

Revenues, net	$	21,478		$	9,218		$	30,696
Cost of revenues		8,164			4,651			12,815
Gross profit		13,314			4,567			17,881
Gross profit %		62.0	%		49.5	%		58.3	%

Allocated expenses:
Engineering and product development		305			116			421
Selling and marketing		11,102			2,009			13,111
Unallocated expenses:
General and administrative		—			—			10,184
Settlement gains		—			—			(1,135	)
Total allocated and unallocated expenses		11,407			2,125			22,581
Income (loss) from operations		1,907			2,442			(4,700	)
Interest expense		—			—			(1,959	)
Interest income		—			—			410
Income (loss) before provision for income taxes	$	1,907		$	2,442		$	(6,249	)

Year Ended December 31, 2024	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total

Revenues, net	$	21,171		$	12,391		$	33,562
Cost of revenues		7,799			6,541			14,340
Gross profit		13,372			5,850			19,222
Gross profit %		63.2	%		47.2	%		57.3	%

Allocated expenses:
Engineering and product development		658			225			883
Selling and marketing		11,140			1,290			12,430
Impairment of goodwill		4,268			—			4,268
Unallocated expenses		—			—			10,896
Total allocated and unallocated expenses		16,066			1,515			28,477
(Loss) income from operations		(2,694	)		4,335			(9,255	)
Interest expense		—			—			(2,107	)
Interest income		—			—			242
Other income		—			—			864
(Loss) income before benefit from income taxes	$	(2,694	)	$	4,335		$	(10,256	)

For the years ended December 31, 2025 and 2024, depreciation and amortization by reportable segment were as follows (in thousands):

	Year Ended December 31,
	2025		2024

Dermatology recurring procedures	$	3,817	$	4,471
Dermatology procedures equipment		305		485
Unallocated expenses		1		12
Total	$	4,123	$	4,968

The following tables present the Company’s revenue disaggregated by geographical region for the years ended December 31, 2025 and 2024 (in thousands). Domestic refers to revenue from customers based in the United States, and foreign revenue is derived from the Company’s distributors primarily in Asia.

Year Ended December 31, 2025	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total

Domestic	$	19,572	$	1,012	$	20,584
China		—		3,355		3,355
Middle East		—		1,896		1,896
Other foreign		1,906		2,955		4,861
Total	$	21,478	$	9,218	$	30,696

Year Ended December 31, 2024	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total

Domestic	$	19,531	$	1,357	$	20,888
China		—		4,069		4,069
Middle East		—		2,766		2,766
Other foreign		1,640		4,199		5,839
Total	$	21,171	$	12,391	$	33,562

As of December 31, 2025 and 2024, total assets by reportable segment were as follows (in thousands):

	December 31,
	2025		2024

Dermatology recurring procedures	$	15,744	$	20,521
Dermatology procedures equipment		6,102		5,081
Other unallocated assets		8,675		9,326
Total	$	30,521	$	34,928

Long-lived assets of $1.3 million were located in international markets, primarily Korea and Japan, as of both December 31, 2025 and 2024, with the remainder located in domestic markets.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended						12 Months Ended
	Oct. 31, 2025	Sep. 30, 2025	Jul. 31, 2024	Jun. 30, 2023	Oct. 31, 2021	Sep. 30, 2021	Dec. 31, 2025	Dec. 31, 2024
Stockholders’ Equity [Abstract]
Preferred stock, stated value (in Dollars per share)							$ 0.1	$ 0.1
Preferred shares outstanding (in Shares)							0	0
Issuance of restricted stock (in Shares)							0	0
Net proceeds from sale of common stock (in Dollars)							$ 3,579	$ 1,943
Senior Term Facility [Member]
Stockholders’ Equity [Abstract]
Warrants issued (in Shares)				80,000		37,362
Exercise price (in Dollars per share)				$ 8.8		$ 18.2
Maximum [Member]
Stockholders’ Equity [Abstract]
Commission as percentage of gross proceeds from sale of shares sold					3.00%
Amount of additional common stock Company may sell under equity distribution agreement (in Dollars)							5,100
At-the-Market Equity Offering [Member]
Stockholders’ Equity [Abstract]
Amount of common stock the Company may sell under equity distribution agreement (in Dollars)					$ 11,000
Issuance of common stock (in Shares)	619,491	1,097,547	665,136
Common stock purchase price (in Dollars per share)	$ 2.3	$ 2.2	$ 3.16
Gross proceeds from sale of common stock (in Dollars)	$ 1,400	$ 2,400	$ 2,100
Net proceeds from sale of common stock (in Dollars)	$ 1,400	$ 2,200	$ 1,900
At-the-Market Equity Offering [Member] \| Maximum [Member]
Stockholders’ Equity [Abstract]
Amount of additional common stock Company may sell under equity distribution agreement (in Dollars)							$ 5,100
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity [Abstract]
Beneficial ownership percentage							9.99%
Preferred stock, stated value (in Dollars per share)							$ 1,000
Preferred stock conversion price (in Dollars per share)							$ 26.9

Business and Geographical Reporting Segments (Tables)

12 Months Ended

Dec. 31, 2025

Business and Geographical Reporting Segments [Abstract]

Segment Reporting Information by Segment

The following tables present results of operations from the Company’s business segments for the periods indicated below (in thousands, except gross profit %):

Year Ended December 31, 2025	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total

Revenues, net	$	21,478		$	9,218		$	30,696
Cost of revenues		8,164			4,651			12,815
Gross profit		13,314			4,567			17,881
Gross profit %		62.0	%		49.5	%		58.3	%

Allocated expenses:
Engineering and product development		305			116			421
Selling and marketing		11,102			2,009			13,111
Unallocated expenses:
General and administrative		—			—			10,184
Settlement gains		—			—			(1,135	)
Total allocated and unallocated expenses		11,407			2,125			22,581
Income (loss) from operations		1,907			2,442			(4,700	)
Interest expense		—			—			(1,959	)
Interest income		—			—			410
Income (loss) before provision for income taxes	$	1,907		$	2,442		$	(6,249	)

Year Ended December 31, 2024	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total

Revenues, net	$	21,171		$	12,391		$	33,562
Cost of revenues		7,799			6,541			14,340
Gross profit		13,372			5,850			19,222
Gross profit %		63.2	%		47.2	%		57.3	%

Allocated expenses:
Engineering and product development		658			225			883
Selling and marketing		11,140			1,290			12,430
Impairment of goodwill		4,268			—			4,268
Unallocated expenses		—			—			10,896
Total allocated and unallocated expenses		16,066			1,515			28,477
(Loss) income from operations		(2,694	)		4,335			(9,255	)
Interest expense		—			—			(2,107	)
Interest income		—			—			242
Other income		—			—			864
(Loss) income before benefit from income taxes	$	(2,694	)	$	4,335		$	(10,256	)

Depreciation and Amortization by Reportable Segment

For the years ended December 31, 2025 and 2024, depreciation and amortization by reportable segment were as follows (in thousands):

	Year Ended December 31,
	2025		2024

Dermatology recurring procedures	$	3,817	$	4,471
Dermatology procedures equipment		305		485
Unallocated expenses		1		12
Total	$	4,123	$	4,968

Disaggregation of Revenue by Geographical Region

Year Ended December 31, 2025	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total

Domestic	$	19,572	$	1,012	$	20,584
China		—		3,355		3,355
Middle East		—		1,896		1,896
Other foreign		1,906		2,955		4,861
Total	$	21,478	$	9,218	$	30,696

Year Ended December 31, 2024	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total

Domestic	$	19,531	$	1,357	$	20,888
China		—		4,069		4,069
Middle East		—		2,766		2,766
Other foreign		1,640		4,199		5,839
Total	$	21,171	$	12,391	$	33,562

Total Assets by Reportable Segment

As of December 31, 2025 and 2024, total assets by reportable segment were as follows (in thousands):

	December 31,
	2025		2024

Dermatology recurring procedures	$	15,744	$	20,521
Dermatology procedures equipment		6,102		5,081
Other unallocated assets		8,675		9,326
Total	$	30,521	$	34,928

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2025

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	December 31,
	2025		2024

State sales, use and other taxes	$	3,757	$	5,142
Compensation and related benefits		1,913		1,781
Warranty obligations		157		213
Professional fees and other		328		228
	$	6,155	$	7,364

Business and Geographical Reporting Segments - Depreciation and Amortization by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Business and Geographical Reporting Segments [Abstract]
Depreciation and Amortization	$ 4,123	$ 4,968
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Business and Geographical Reporting Segments [Abstract]
Depreciation and Amortization	3,817	4,471
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Business and Geographical Reporting Segments [Abstract]
Depreciation and Amortization	305	485
Unallocated Expenses [Member]
Business and Geographical Reporting Segments [Abstract]
Depreciation and Amortization	$ 1	$ 12

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References + Details

Commitments and Contingencies (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2022	Dec. 31, 2025	Dec. 31, 2024	Oct. 22, 2024	May 06, 2022
Commitments and Contingencies [Abstract]
Employer contribution amount		$ 300	$ 300
Revenues		30,696	$ 33,562
Development Agreement [Member]
Commitments and Contingencies [Abstract]
Future milestone payments		0
Tax Period from August 2017 through November 2022 [Member]
Commitments and Contingencies [Abstract]
Appellate bond cash collateral				$ 1,300
Tax Period from August 2017 through November 2022 [Member] \| Assessment One [Member]
Commitments and Contingencies [Abstract]
Estimated tax positions subject to audit		5,600
Tax Period from August 2017 through November 2022 [Member]
Commitments and Contingencies [Abstract]
Accrued amount including penalties and interest		600
Tax Period from August 2017 through November 2022 [Member] \| Assessment One [Member]
Commitments and Contingencies [Abstract]
Appellate bond cash collateral					$ 1,300
Tax Period from August 2017 through November 2022 [Member] \| Assessment Two [Member]
Commitments and Contingencies [Abstract]
Assessment amount		2,600
Tax period from June 2018 through June 2022 [Member]
Commitments and Contingencies [Abstract]
Estimated tax positions subject to audit		$ 2,400
TheraClear Corporation [Member]
Commitments and Contingencies [Abstract]
Future earnout payment due upon revenue target	$ 1,000
Subsequent period of gross profit for future royalty payments		4 years
Royalty percentage		5.00%
Aggregate royalties paid		$ 3,000
TheraClear Corporation [Member] \| International [Member]
Commitments and Contingencies [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	25.00%
TheraClear Corporation [Member] \| Maximum [Member]
Commitments and Contingencies [Abstract]
Future milestone payments	$ 500
Future earnout payments	3,000
Future royalty payments	$ 20,000
TheraClear Corporation [Member] \| Maximum [Member] \| Domestic [Member]
Commitments and Contingencies [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	20.00%
TheraClear Corporation [Member] \| Minimum [Member]
Commitments and Contingencies [Abstract]
Revenues		$ 2,500
TheraClear Corporation [Member] \| Minimum [Member] \| Domestic [Member]
Commitments and Contingencies [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	10.00%

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2025
Fair Value Measurements [Abstract]
Fair Value Measurements	4. Fair Value Measurements The carrying values of cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, and accounts payable on the Company’s consolidated balance sheets approximated their fair values as of December 31, 2025 and 2024 due to their short-term nature. The carrying value of the Company’s Senior Term Facility (see Note 10) approximated its fair value as of December 31, 2025 and 2024 due to its variable interest rate.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities:
Net loss	$ (6,261)	$ (10,086)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	4,123	4,968
Impairment of goodwill	0	4,268
Amortization of operating lease right-of-use assets	344	339
Amortization of deferred financing costs and debt discount	157	148
Provision for credit losses	129	(182)
Stock-based compensation expense	643	427
Loss on disposal of property and equipment	92	49
Settlement gains	(1,135)	0
Inventory write-off	0	162
Deferred income taxes	0	(186)
Changes in operating assets and liabilities:
Accounts receivable	1,003	(631)
Inventories	(288)	572
Prepaid expenses and other assets	(252)	(189)
Accounts payable	350	(954)
Accrued expenses and other liabilities	(1,248)	1,859
Deferred revenues	(123)	(57)
Operating lease liabilities	(328)	(319)
Net cash (used in) provided by operating activities	(2,794)	188
Cash flows from investing activities:
Purchase of property and equipment	(1,468)	(1,636)
Net cash used in investing activities	(1,468)	(1,636)
Cash flows from financing activities:
Payment of contingent consideration	0	(18)
Sale of common stock, net of offering costs	3,579	1,943
Net cash provided by financing activities	3,579	1,925
Net (decrease) increase in cash, cash equivalents and restricted cash	(683)	477
Cash, cash equivalents and restricted cash at beginning of year	8,595	8,118
Cash, cash equivalents and restricted cash at end of year	7,912	8,595
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	1,811	1,973
Supplemental schedule of non-cash operating, investing and financing activities:
Transfer of property and equipment to inventories	280	307
Accrued equity issuance costs included in accounts payable	25	0
Write-off of contingent consideration to settlement gains	1,176	0
Write-off of intangible assets to settlement gains	725	0
Accrued exit fee recorded as debt discount	0	150
Accrued payment of contingent consideration	0	44
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$ 0	$ 977

Consolidated Statements of Changes in Stockholders’ Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In-Capital [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2023	$ 4	$ 250,742	$ (238,058)	$ 12,688
Beginning balance (in Shares) at Dec. 31, 2023	3,506,025
Net loss				(3,366)
Ending balance at Mar. 31, 2024				9,434
Beginning balance at Dec. 31, 2023	$ 4	250,742	(238,058)	12,688
Beginning balance (in Shares) at Dec. 31, 2023	3,506,025
Net loss				(3,457)
Ending balance at Jun. 30, 2024				9,506
Beginning balance at Dec. 31, 2023	$ 4	250,742	(238,058)	12,688
Beginning balance (in Shares) at Dec. 31, 2023	3,506,025
Net loss				(5,531)
Ending balance at Sep. 30, 2024				9,401
Beginning balance at Dec. 31, 2023	$ 4	250,742	(238,058)	12,688
Beginning balance (in Shares) at Dec. 31, 2023	3,506,025
Stock-based compensation expense	$ 0	427	0	427
Sale of common stock, net of offering costs	$ 0	1,943	0	1,943
Sale of common stock, net of offering costs (in Shares)	665,136
Net loss	$ 0	0	(10,086)	(10,086)
Ending balance at Dec. 31, 2024	$ 4	253,112	(248,144)	$ 4,972
Ending balance (in Shares) at Dec. 31, 2024	4,171,161			4,171,161
Beginning balance at Mar. 31, 2024				$ 9,434
Net loss				(91)
Ending balance at Jun. 30, 2024				9,506
Net loss				(2,074)
Ending balance at Sep. 30, 2024				9,401
Beginning balance at Dec. 31, 2024	$ 4	253,112	(248,144)	4,972
Net loss				(2,122)
Ending balance at Mar. 31, 2025				2,979
Beginning balance at Dec. 31, 2024	$ 4	253,112	(248,144)	$ 4,972
Beginning balance (in Shares) at Dec. 31, 2024	4,171,161			4,171,161
Net loss				$ (4,697)
Ending balance at Jun. 30, 2025				532
Beginning balance at Dec. 31, 2024	$ 4	253,112	(248,144)	$ 4,972
Beginning balance (in Shares) at Dec. 31, 2024	4,171,161			4,171,161
Stock-based compensation expense	$ 0	643	0	$ 643
Sale of common stock, net of offering costs	$ 2	3,552	0	3,554
Sale of common stock, net of offering costs (in Shares)	1,717,038
Net loss	$ 0	0	(6,261)	(6,261)
Ending balance at Dec. 31, 2025	$ 6	$ 257,307	$ (254,405)	$ 2,908
Ending balance (in Shares) at Dec. 31, 2025	5,888,199			5,888,199
Beginning balance at Mar. 31, 2025				$ 2,979
Net loss				(2,575)
Ending balance at Jun. 30, 2025				$ 532

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References + Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

Income Taxes - Reconciliation of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Taxes [Abstract]
Federal tax expense at statutory rate (in Dollars)	$ (1,312)
Federal tax expense at statutory rate	21.00%	21.00%
State and local tax, net of federal benefit		(0.12%)
Permanent differences		(1.15%)
Change in valuation allowance (in Dollars)	$ 738
Change in valuation allowance	(11.81%)	(14.94%)
Nondeductible meal and entertainment expenses (in Dollars)	$ 97
Nondeductible meal and entertainment expenses	(1.55%)
Nondeductible incentive stock option compensation (in Dollars)	$ 83
Nondeductible incentive stock option compensation	(1.33%)
Other (in Dollars)	$ 0
Other	0.00%	(3.13%)
NOL expiration (in Dollars)	$ 476
NOL expiration	(7.62%)
Other (in Dollars)	$ (79)
Other	1.27%
(Provision for) benefit from income taxes (in Dollars)	$ 12	$ (170)
Effective income tax rate	(0.19%)	1.66%
California [Member]
Income Taxes [Abstract]
State and local tax, net of federal benefit (in Dollars)	$ 0
State and local tax, net of federal benefit	0.00%
New York State [Member]
Income Taxes [Abstract]
State and local tax, net of federal benefit (in Dollars)	$ 0
State and local tax, net of federal benefit	0.00%
New Jersey [Member]
Income Taxes [Abstract]
State and local tax, net of federal benefit (in Dollars)	$ 0
State and local tax, net of federal benefit	0.00%
Florida [Member]
Income Taxes [Abstract]
State and local tax, net of federal benefit (in Dollars)	$ 0
State and local tax, net of federal benefit	0.00%
Other [Member]
Income Taxes [Abstract]
State and local tax, net of federal benefit (in Dollars)	$ 9
State and local tax, net of federal benefit	(0.15%)

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 7,912	$ 7,261
Restricted cash	0	1,334
Accounts receivable, net of allowance for credit losses of $551 and $433 at December 31, 2025 and 2024, respectively	4,121	5,253
Inventories	2,814	2,246
Prepaid expenses and other current assets	753	501
Total current assets	15,600	16,595
Property and equipment, net	8,964	10,061
Operating lease right-of-use assets	920	1,264
Intangible assets, net	3,377	5,348
Goodwill	1,429	1,429
Other assets	231	231
Total assets	30,521	34,928
Current liabilities:
Current portion of long-term debt	15,349	0
Accounts payable	2,758	2,433
Accrued expenses and other current liabilities	6,155	7,364
Deferred revenues	2,248	2,241
Current portion of operating lease liabilities	231	328
Current portion of contingent consideration	0	1,030
Total current liabilities	26,741	13,396
Long-term debt, net	0	15,192
Deferred revenues and other liabilities	184	353
Operating lease liabilities, net of current portion	688	919
Contingent consideration, net of current portion	0	96
Total liabilities	27,613	29,956
Commitments and contingencies (Note 11)
Stockholders’ equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 5,888,199 and 4,171,161 shares issued and outstanding at December 31, 2025 and 2024, respectively	6	4
Additional paid-in capital	257,307	253,112
Accumulated deficit	(254,405)	(248,144)
Total stockholders’ equity	2,908	4,972
Total liabilities and stockholders’ equity	$ 30,521	$ 34,928

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Restricted Cash

	December 31,
	2025		2024

Cash and cash equivalents	$	7,912	$	7,261
Restricted cash		—		1,334
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	7,912	$	8,595

Allowance for Credit Losses

The activity in the allowance for credit losses is summarized as follows (in thousands):

	December 31,
	2025			2024

Balance, beginning of year	$	433		$	222
Provision for expected losses		134			(179	)
Write-offs charged against the allowance		(16	)		141
Other adjustments		—			249
Balance, end of year	$	551		$	433

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2025 and 2024 is summarized as follows (in thousands):

	December 31,
	2025			2024

Balance, beginning of year	$	315		$	303
Additions		100			156
Expirations and claims satisfied		(195	)		(144	)
Total		220			315
Less current portion within accrued expenses and other current liabilities		(157	)		(213	)
Balance within deferred revenues and other liabilities	$	63		$	102

Disaggregation of Revenue

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2025		2024

Dermatology recurring procedures	$	21,478	$	21,171
Dermatology procedures equipment		9,218		12,391
Total net revenues	$	30,696	$	33,562

Future Undiscounted Fixed Treatment Code Payments from International Dermatology Recurring Procedures

Years ending December 31:
2026	$	1,983
2027		1,798
2028		1,236
2029		266
	$	5,283

Antidilutive Securities Excluded from Computation of Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2025		2024

Stock options		725,726		521,726
Common stock warrants		80,000		80,000
Restricted stock units		2,265		2,265
		807,991		603,991

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Board of Directors administers its cybersecurity risk oversight function directly through our Audit Committee (the “Committee”). The Committee has primary responsibility for overseeing our risk management practices, programs, policies, and procedures related to data privacy, data protection, and cybersecurity. The Committee reviews and evaluates the processes utilized by management to identify and assess the material internal and external risks that may affect our business.
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our Board of Directors administers its cybersecurity risk oversight function directly through our Audit Committee (the “Committee”). The Committee has primary responsibility for overseeing our risk management practices, programs, policies, and procedures related to data privacy, data protection, and cybersecurity. The Committee reviews and evaluates the processes utilized by management to identify and assess the material internal and external risks that may affect our business. The Committee regularly discusses with management, legal counsel, and the internal audit department our major risk exposures. This includes potential financial impact on us and the steps taken to monitor and control those risks. Reviews with management are done annually, which includes a summary of legal and regulatory compliance matters and risk management activities, and a review of our cybersecurity program. Additionally, the Committee oversees the process by which our Board of Directors is informed regarding the risks facing us and coordinates with our legal counsel to ensure our Board of Directors receives regular risk assessment updates from management. Our IT Manager has been designated as our Chief Information Security Officer (“CISO”), who has been with the Company for over five years and has many years of experience in information technology, including relevant experience overseeing IT systems and managing technology-related risks, and is responsible for identifying, assessing and managing our risks from cybersecurity threats. The CISO is supported by our outside IT consulting firm and its cybersecurity team, which includes personnel experienced in cybersecurity, security operations and incident management. The CISO reports to the Chief Accounting Officer (“CAO”), who provides the Committee with bi-annual updates about our cybersecurity program and material risks.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Committee regularly discusses with management, legal counsel, and the internal audit department our major risk exposures. This includes potential financial impact on us and the steps taken to monitor and control those risks. Reviews with management are done annually, which includes a summary of legal and regulatory compliance matters and risk management activities, and a review of our cybersecurity program. Additionally, the Committee oversees the process by which our Board of Directors is informed regarding the risks facing us and coordinates with our legal counsel to ensure our Board of Directors receives regular risk assessment updates from management.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our IT Manager has been designated as our Chief Information Security Officer (“CISO”), who has been with the Company for over five years and has many years of experience in information technology, including relevant experience overseeing IT systems and managing technology-related risks, and is responsible for identifying, assessing and managing our risks from cybersecurity threats.
Cybersecurity Risk Role of Management [Text Block]	Our IT Manager has been designated as our Chief Information Security Officer (“CISO”), who has been with the Company for over five years and has many years of experience in information technology, including relevant experience overseeing IT systems and managing technology-related risks, and is responsible for identifying, assessing and managing our risks from cybersecurity threats. The CISO is supported by our outside IT consulting firm and its cybersecurity team, which includes personnel experienced in cybersecurity, security operations and incident management. The CISO reports to the Chief Accounting Officer (“CAO”), who provides the Committee with bi-annual updates about our cybersecurity program and material risks.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Risk Management and Strategy Processes for identifying and assessing cybersecurity risks The CISO, with the support of the outside consultant’s cybersecurity team and the owners of information technology across the business, monitors current events and trends related to cybersecurity and assesses any potential impact on current systems and operations. There are several processes in place to monitor and review our systems, including third-party solutions, to identify potential risks. Third-party service providers are required to notify us in the event of a cybersecurity incident within their systems, and annual reviews are conducted on our critical third-party vendors. Cybersecurity risks, threats, and incidents, including those from third-party service providers, are tracked and regularly provided to the CISO. Processes for managing cybersecurity risks The cybersecurity team tracks risks and incidents related to cybersecurity until the risk is mitigated to an acceptable level or fully remediated. When risks are identified, the cybersecurity team oversees mitigation plans with the risk owner which are communicated to necessary teams and remediation steps are taken. Processes for incorporating cybersecurity risks into the overall risk management process Our process for identifying, assessing, and managing risks related to cybersecurity is incorporated into our IT processes. The Risk Management team meets at least annually with cybersecurity leadership to discuss cybersecurity related risks identified and the potential likelihood and severity of each risk. Through this process, cybersecurity risks are presented to the executive leadership team, including the Chief Executive Officer (“CEO”) and CAO, as well as reported to the Committee. Currently, we are not aware of any risks from cybersecurity threats, or from previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect the Company.
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The cybersecurity team tracks risks and incidents related to cybersecurity until the risk is mitigated to an acceptable level or fully remediated. When risks are identified, the cybersecurity team oversees mitigation plans with the risk owner which are communicated to necessary teams and remediation steps are taken.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	The Risk Management team meets at least annually with cybersecurity leadership to discuss cybersecurity related risks identified and the potential likelihood and severity of each risk. Through this process, cybersecurity risks are presented to the executive leadership team, including the Chief Executive Officer (“CEO”) and CAO, as well as reported to the Committee.
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]	Currently, we are not aware of any risks from cybersecurity threats, or from previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect the Company.

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2025
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Legal Matters In the ordinary course of business, the Company is routinely a defendant in or party to pending and threatened legal actions and proceedings, including actions brought on behalf of various classes of claimants. These actions and proceedings are generally based on alleged violations of employment, contract, and other laws. In some of these actions and proceedings, claims for substantial monetary damages are asserted against the Company. In the ordinary course of business, the Company is also subject to regulatory and governmental examinations, information gathering requests, inquiries, investigations, and threatened legal actions and proceedings. In connection with formal and informal inquiries by federal, state, local and foreign agencies, the Company receives numerous requests, subpoenas and orders for documents, testimony, and information in connection with various aspects of its activities. Accrued State Sales and Use Tax Matters The Company records state sales tax collected and remitted for its customers on dermatology procedures equipment sales on a net basis, excluded from revenue. The Company’s sales tax expense that is not presently being collected and remitted for the recurring revenue business is recorded in general and administrative expenses within the consolidated statements of operations. The Company believes its state sales and use tax accruals have been properly recognized such that, if the Company’s arrangements with customers are deemed more likely than not that the Company would not be exempt from sales tax in a particular state, the basis for measurement of the state sales and use tax is calculated in accordance with ASC 405, Liabilities, as a transaction tax. If and when the Company is successful in defending itself or in settling the sales tax obligation for a lesser amount, the reversal of this liability is to be recorded in the period the settlement is reached. In the ordinary course of business, the Company is, from time to time, subject to audits performed by state taxing authorities. These actions and proceedings are generally based on the position that the arrangements entered into by the Company are subject to sales and use tax rather than exempt from tax under applicable law. The Company has outstanding assessments from the states of New York and California aggregating to $5.6 million including penalties and interest. The audits cover the period from August 2017 through February 2025. In January 2021, the Company received notification that an administrative state judge in New York issued an opinion finding in favor of the Company that the sale of XTRAC treatment codes was not taxable as sales tax with respect to that state’s first assessment. The relevant taxing authority filed an appeal of the administrative law judge’s finding and, following the submission of legal briefs by both sides and oral argument held in January 2022, on May 6, 2022, the Company received a written decision from the Tribunal overturning the favorable sales tax determination of the administrative law judge. The Company appealed the Tribunal’s decision to the New York State Appellate Division (“Appellate Division”), and posted the required appellate bond in the form of cash collateral in the amount of $1.3 million. Oral argument was held by the Appellate Division on January 18, 2024. On March 8, 2024, the Company received a decision from the Appellate Division ruling against it in the matter of its sales tax appeal, affirming the Tribunal’s ruling that the Company’s sale of XTRAC treatment codes is subject to sales tax. The Appellate Division concluded that, through the usage arrangements, the Company’s customers had possession of the laser devices and had a license and ability to use the laser devices. The Appellate Division also agreed with the Tribunal that the primary function analysis was not applicable in this matter. On April 11, 2024, the Company filed a motion for leave to appeal the Appellate Division’s decision to the New York State Court of Appeals (“Court of Appeals”). On October 22, 2024, in an unsigned one-line decision, the Court of Appeals denied the Company’s motion to appeal the Appellate Division ruling. Therefore, the adverse decision stands and New York executed on the appellate bond the Company posted for $1.3 million. As of December 31, 2025, the Company has a remaining accrual of $0.6 million including penalties and interest as a result of the Appellate Division ruling. The Company is in the administrative process of appeal with respect to the remaining $2.6 million of assessments in the state of New York. The Company believes that the Appellate Division ruling provides an avenue for challenging the pending audit periods and subsequent periods, provided the Company can show that the value of the equipment provided to customers is incidental to the overall value of the non-taxable services that are provided, or should be treated similarly to pharmaceutical treatments, which are generally exempt from sales tax. The state of California has made aggregate assessments of $2.4 million including penalties and interest. The audits cover the period from June 2018 through June 2022. The Company is in the administrative process of appeal in this jurisdiction as well. In those states where the Company did not or may not prevail with the defenses it has proposed, and in the event there is a determination that the true object of the Company’s recurring revenue model is not exempt from sales taxes and is not a prescription medicine, or the Company does not have other defenses where the Company prevails, the Company may be subject to sales taxes in those particular states for previous years and in the future, plus potential interest and penalties. The precise scope, timing and time periods at issue, as well as the final outcomes of the investigations and judicial proceedings, remain uncertain. Accordingly, the Company’s estimate may change from time to time, and actual losses could vary. Employee 401(k) Savings Plan The Company sponsors a 401(k) defined contribution retirement savings plan that covers all eligible employees who have met the minimum age and service requirements. Under the plan, eligible employees may contribute a portion of their annual compensation into the plan up to IRS annual limits. The Company has elected to make matching contributions to the plan based on a percentage of the employee’s contribution. For each of the years ended December 31, 2025 and 2024, the Company’s contributions to the plan were $0.3 million. Contingent Consideration In connection with the Company’s acquisition of certain assets related to the TheraClear devices, Theravant was eligible to receive up to $3.0 million in future earnout payments upon the achievement of certain annual net revenue milestones ($1.0 million of which was due upon the earlier of achieving a revenue target or July 2025), up to $20.0 million in future royalty payments based upon a percentage of gross profit from future domestic sales ranging from 10-20%, 25% of gross profit from international sales over the subsequent four-year period, and up to $0.5 million in future milestone payments upon the achievement of certain commercialization related targets. Pursuant to the Theravant Settlement executed in October 2025 (see Note 8), the Company was released from all obligations related to contingent consideration. Royalty Payments As additional consideration to the mutual releases contained within the Theravant Settlement, the Company will owe Theravant a royalty equal to 5% of sales of TheraClear® X devices, payable quarterly in arrears, starting on the later of January 1, 2027 or when the Company first achieves annual domestic revenue of more than $2.5 million from the sale or placement of TheraClear® X devices and ending on the first to occur of (i) the Company has paid aggregate royalties of $3.0 million to Theravant or (ii) the Company commercially launches a new TheraClear® X device and replaces the current TheraClear® X device (as defined in the Theravant Settlement). No royalties were incurred or considered probable of being incurred through December 31, 2025.

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2025

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Principles of Consolidation

Use of Estimates

Concentrations of Credit Risk and Major Customers

Cash and Cash Equivalents

Restricted Cash

	December 31,
	2025		2024

Cash and cash equivalents	$	7,912	$	7,261
Restricted cash		—		1,334
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	7,912	$	8,595

Accounts Receivable and Allowance for Credit Losses

Inventories

Property and Equipment, net

Intangible Assets

Goodwill

Impairment of Long-Lived Assets and Intangibles

Fair Value Measurements

•

Level 1 – quoted market prices in active markets for identical assets or liabilities.

•

Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

Accrued Warranty Costs

The activity in the warranty accrual during the years ended December 31, 2025 and 2024 is summarized as follows (in thousands):

	December 31,
	2025			2024

Balance, beginning of year	$	315		$	303
Additions		100			156
Expirations and claims satisfied		(195	)		(144	)
Total		220			315
Less current portion within accrued expenses and other current liabilities		(157	)		(213	)
Balance within deferred revenues and other liabilities	$	63		$	102

Debt Issuance Costs

Contingent Consideration

Revenue Recognition

•

identification of the contract, or contracts, with a customer;

•

identification of the performance obligations in the contract;

•

determination of the transaction price;

•

allocation of the transaction price to the performance obligations in the contract; and

•

recognition of revenue when, or as, performance obligations are satisfied.

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2025		2024

Dermatology recurring procedures	$	21,478	$	21,171
Dermatology procedures equipment		9,218		12,391
Total net revenues	$	30,696	$	33,562

Years ending December 31:
2026	$	1,983
2027		1,798
2028		1,236
2029		266
	$	5,283

With respect to contract acquisition costs, the Company applies the practical expedient and expenses these costs immediately.

Engineering and Product Development

Engineering and product development costs associated with research, new product development and product redesign are expensed as incurred.

Advertising Costs

Stock-Based Compensation

The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the requisite service period of the awards.

Income Taxes

Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2025		2024

Stock options		725,726		521,726
Common stock warrants		80,000		80,000
Restricted stock units		2,265		2,265
		807,991		603,991

Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted

Accounting Pronouncements Recently Adopted

Recent Accounting Pronouncements Not Yet Adopted

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Consolidated Statements of Operations [Abstract]
Revenues, net	$ 30,696	$ 33,562
Cost of revenues	12,815	14,340
Gross profit	17,881	19,222
Operating expenses:
Engineering and product development	421	883
Selling and marketing	13,111	12,430
General and administrative	10,184	10,896
Impairment of goodwill	0	4,268
Settlement gains	(1,135)	0
Total operating expenses	22,581	28,477
Loss from operations	(4,700)	(9,255)
Interest expense	(1,959)	(2,107)
Interest income	410	242
Other income	0	864
Other (expense), income net	(1,549)	(1,001)
Loss before (provision for) benefit from income taxes	(6,249)	(10,256)
(Provision for) benefit from income taxes	(12)	170
Net loss	$ (6,261)	$ (10,086)
Net loss per share of common stock - basic (in Dollars per share)	$ (1.35)	$ (2.65)
Net loss per share of common stock - diluted (in Dollars per share)	$ (1.35)	$ (2.65)
Weighted average shares of common stock outstanding - basic (in Shares)	4,650,556	3,807,186
Weighted average shares of common stock outstanding - diluted (in Shares)	4,650,556	3,807,186

Business and Geographical Reporting Segments - Total Assets by Reportable Segment (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
Business and Geographical Reporting Segments [Abstract]
Assets	$ 30,521	$ 29,493	$ 33,033	$ 34,928	$ 39,383	$ 38,759	$ 39,226
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Business and Geographical Reporting Segments [Abstract]
Assets	15,744			20,521
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Business and Geographical Reporting Segments [Abstract]
Assets	6,102			5,081
Other Unallocated Assets [Member]
Business and Geographical Reporting Segments [Abstract]
Assets	$ 8,675			$ 9,326

- Definition

Amount of asset recognized for present right to economic benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 64
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481620/480-10-55-64

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Intangible Assets and Goodwill (Tables)

12 Months Ended

Dec. 31, 2025

Intangible Assets and Goodwill [Abstract]

Components of Intangible Assets

Intangible assets consist of the following (in thousands):

December 31, 2025	Gross Carrying Value		Accumulated Amortization			Net Book Value

Core technology	$	5,700	$	(5,700	)	$	—
Product technology		2,000		(2,000	)		—
Customer relationships		6,900		(6,900	)		—
Tradenames		1,500		(1,500	)		—
Pharos customer lists		5,314		(1,937	)		3,377
	$	21,414	$	(18,037	)	$	3,377

December 31, 2024	Gross Carrying Value		Accumulated Amortization			Net Book Value

Core technology	$	5,700	$	(5,415	)	$	285
Product technology		4,808		(3,984	)		824
Customer relationships		6,900		(6,555	)		345
Tradenames		1,500		(1,425	)		75
Pharos customer lists		5,314		(1,495	)		3,819
	$	24,222	$	(18,874	)	$	5,348

Estimated Future Amortization Expense for Intangible Assets

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years (in thousands):

Years ending December 31:
2026	$	443
2027	$	443
2028	$	443
2029	$	443
2030	$	443

Components of Goodwill

Goodwill consists of the following (in thousands):

	December 31,
	2025		2024

Dermatology recurring procedures segment	$	584	$	584
Dermatology procedures equipment segment		845		845
	$	1,429	$	1,429

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

Income Taxes - Net Operating Loss Carryforwards (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Federal [Member]
Income Taxes [Abstract]
Operating loss carryforwards	$ 206,801	$ 203,490
State [Member]
Income Taxes [Abstract]
Operating loss carryforwards	$ 68,999	$ 62,819

Intangible Assets and Goodwill - Components of Goodwill (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
Intangible Assets and Goodwill [Abstract]
Goodwill	$ 1,429	$ 1,429	$ 1,429	$ 1,429	$ 5,697	$ 5,697	$ 5,697
Dermatology Recurring Procedures [Member]
Intangible Assets and Goodwill [Abstract]
Goodwill	584			584
Dermatology Procedures Equipment [Member]
Intangible Assets and Goodwill [Abstract]
Goodwill	$ 845			$ 845

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 740
-Name Accounting Standards Codification
-Section 55
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478064/805-740-55-13

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-39

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

Income Taxes - Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Current:
Federal	$ 0	$ 0
State	12	16
Current income taxes	12	16
Deferred:
Federal	0	(107)
State	0	(79)
Deferred income tax	0	(186)
(Provision for) benefit from income taxes (in Dollars)	$ 12	$ (170)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2025

Income Taxes [Abstract]

Income Taxes

14. Income Taxes

Loss before income taxes was $6.2 million and $10.3 million for the years ended December 31, 2025 and 2024, respectively. All pretax loss was generated from operations within the United States.

Income tax expense consists of the following (in thousands):

	Year Ended December 31,
	2025		2024

Current:
Federal	$	—	$	—
State		12		16
		12		16
Deferred:
Federal		—		(107	)
State		—		(79	)
		—		(186	)
Provision for (benefit from) income taxes	$	12	$	(170	)

Cash paid for income taxes, net of refunds received, by jurisdiction pursuant to the disclosure requirements of ASU 2023-09 is as follows (in thousands):

	Year Ended December 31,
	2025		2024
Federal	$	—	$	—
State
Texas		9		10
Cash paid for income taxes, net of refunds received	$	9	$	10

Deferred tax assets and liabilities are determined based on the differences between the consolidated financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.

Significant components of the Company’s deferred tax liability for federal income taxes consist of the following (in thousands):

	December 31,
	2025			2024
Deferred tax assets:
Net operating loss carryforwards	$	49,215		$	46,295
Intangible assets		2,114			2,308
Inventories		73			57
Reserves and accrued expenses		1,539			2,068
Stock-based compensation		220			162
Operating lease liabilities		242			305
Interest expense limitation carryover		1,270			1,024
Goodwill		318			239
Property and equipment		264			—
Gross deferred tax assets		55,255			52,458
Less: valuation allowance		(55,013	)		(51,671	)
		242			787
Deferred tax liabilities:
Property and equipment		—			(478	)
Operating lease right-of-use assets		(242	)		(309	)
Gross deferred tax liabilities		(242	)		(787	)
Net deferred tax liability	$	—		$	—

In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company’s deferred tax assets as of December 31, 2025. The valuation allowance increased by $3.3 million during the year ended December 31, 2025. The Company does not have unrecognized tax benefits as of December 31, 2025 or 2024. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

The Company had net operating loss (“NOL”) carryforwards for federal and state income tax purposes as follows (in thousands):

	December 31,
	2025		2024

Federal	$	206,801	$	203,490
State	$	68,999	$	62,819

The NOL carryforwards generated prior to 2018 began to expire for federal income tax purposes and begin expiring in 2030 for state income tax purposes. Federal and many state NOLs generated in 2018 and into the future now have an indefinite life.

The NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception.

	Year Ended December 31, 2025

Federal tax expense at statutory rate	$	(1,312	)	21.00	%
State and local tax, net of federal benefit
California		—		—	%
New York State		—		—	%
New Jersey		—		—	%
Florida		—		—	%
Other		9		(0.15	)%
Change in valuation allowance		738		(11.81	)%
Nontaxable or nondeductible items
Nondeductible meal and entertainment expenses		97		(1.55	)%
Nondeductible incentive stock option compensation		83		(1.33	)%
Other		—		—	%
Other adjustments
NOL expiration		476		(7.62	)%
Other		(79	)	1.27	%
Effective income tax rate	$	12		(0.19	)%

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:

	Year Ended December 31, 2024

Federal tax expense at statutory rate	21.00	%
State tax, net of federal benefit	(0.12)	%
Permanent differences	(1.15)	%
Other difference and true ups	(3.13)	%
Change in valuation allowance	(14.94)	%
Effective income tax rate	1.66	%

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022 (“IRA”). The IRA contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock repurchases. The provisions of the IRA did not have an impact on the Company’s consolidated financial statements for the years ended December 31, 2025 and 2024, as the Company currently does not qualify as a large corporation for the 15% alternative minimum tax and there were no stock repurchases. The Company will monitor its operations for changes that could impact the applicability of the IRA provisions in future tax years.

On July 4, 2025, the One Big Beautiful Bill Act was signed into law in the United States, which contains a broad range of tax reform provisions affecting businesses. The legislation does not have a material impact on the Company’s financial statements.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details